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General introduction
1
Parts of this chapter are based on book Chapter 39 Prostate 
in Grainger & Allison’s Diagnostic Radiology; Elsevier 2014, 
by J.G.R. Bomers, L.K. Bittencourt, G. Villeirs and J.O. Barentsz.
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Prostate anatomy and histology
The prostate gland surrounds the proximal part of the urethra and is located directly 
caudal from the bladder and ventral of the rectum (Figure 1). The seminal vesicles lie 
posterosuperiorly between the bladder and the rectum. The ejaculatory ducts pass 
through the gland and end in the prostatic urethra at the verumontanum. The neuro- 
vascular bundles, responsible for erectile function, pass from superior to inferior 
along both posterolateral sides of the prostate.
 In craniocaudal direction, the prostate can be divided into three parts (Figure 1B). 
The cranial part of the prostate is referred to as the base, the middle part is the 
midprostate and the caudal part is called the apex. Anatomically, the prostate consists 
of three different zones: the peripheral zone, the transition zone and the central zone. 
Ventral to the prostate lies the anterior fibromuscular stroma, mainly composed of 
smooth muscle cells and connective tissue; it does not contain glandular tissue.
 The peripheral zone is located posteriorly and inferiorly and around 70–80% of 
the tumor foci are located in this zone (1,2). The transition zone is located interiorly 
and surrounds the prostatic urethra. The central zone is located posterior and superior 
of the transition zone. Approximately 20% of PCa foci arise from the transition zone 
and 10% arises from the central zone (3).
 The Gleason grading system is the gold standard for the determination of the 
biological aggressiveness of PCa (4). This system is based on a description of cancer 
cell architecture at low-power optic microscopy. Five different microscopic patterns 
Figure 1 A: Axial T2-weighted MR image showing the prostate and its zonal anatomy. 
The peripheral zone (P) is shown as a crescent-shaped hyperintense structure; the central 
gland (C) is depicted as a structure with heterogeneous signal intensity. B: Sagittal T2-weighted 
image showing the craniocaudal segmentation of the prostate and its relation to the adjacent 
structures.
A B
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can be described, increasing from less (Gleason grade 1; well-differentiated uniform 
glands) to most aggressive (Gleason grade 5; poorly differentiated, anaplastic or 
even no presence of prostate gland cells).
 The Gleason score (GS) is calculated by the sum of the two most prevalent patterns, 
ranging from 2 to 10: for example, Gleason 3+4=7. The GS is considered a strong 
clinical predictor for the prognosis of the patient and is used for decisions in further 
patient treatment. Gleason grades 4 and 5 and GS >7 have the worst prognosis (4-6).
Prostate cancer 
With almost 10,500 new cases and approximately 2500 deaths in the Netherlands for 
2015 prostate cancer (PCa) is the most common cancer in males older than 45 years, 
and the third cause of cancer-related death (7). Presently, one in six men will be 
diagnosed with PCa at a certain moment in their life. 
 The last three decades have seen a steep rise in PCa incidence. To a certain 
extent this can be explained by the introduction of prostate specific antigen (PSA) 
test, by the development of improved diagnostic imaging exams and by the 
improvement in demographic information systems. The improvement in overall life 
expectancy and the trend to apply lower cut-off levels for the PSA blood level test, will 
further increase the number of men diagnosed with PCa (8). 
 Nowadays, an abnormal digital rectal examination (DRE), an elevated PSA level 
or anomalous changes in PSA level and dynamics (i.e. doubling time or PSA velocity) 
are biological signs indicating an increased risk of PCa. However, these techniques 
are being considered of restricted accuracy in PCa detection. DRE is affected by 
considerable inter-observer variability, and is limited to the evaluation of lesions in the 
posterior and lateral peripheral zone. The specificity of PSA testing is of limited value, 
as 70–80% of patients with slight PSA elevation (>4.0 ng/mL) have benign prostatic 
hyperplasia (BPH) or prostatitis rather than PCa.
 In general, when there is an increased clinical risk of PCa, systematic random 
transrectal ultrasound (TRUS) biopsies are performed. However, undersampling is a 
limitation. Even with the most aggressive biopsy schemes, detection rates of only 
23–42% after the first biopsy session, until 18% after the fourth biopsy session, are 
reported (9). Furthermore, significant underscoring of tumor aggression is a notable 
limitation of systematic biopsies (10). This is caused by sampling errors, tumor 
multifocality and heterogeneity of the lesion or a combination of these factors. As 
histopathology results obtained from TRUS-guided biopsy are commonly used in 
nomograms for risk assessment and prognosis in PCa, an inaccurate assessment of 
the true tumor aggression will lead to wrong treatment options.
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Multi-parametric MRI of the prostate
The limitations of DRE, PSA, TRUS and systematic biopsy schemes have raised 
interest in the development of prostate magnetic resonance imaging (MRI). In the 
assessment of PCa, MRI can be used for multiple purposes: detection of primary or 
recurrent cancer, localization and staging of local and distant disease. Since the first 
prostate MRI examinations in the 1980s, prostate MRI has evolved to a mature 
imaging modality. 
 In general, high-resolution T2-weighted images are used to depict the anatomy 
of the prostate and its surrounding structures like the seminal vesicles, bladder and 
rectal wall (Figure 2A). The healthy peripheral zone has a homogeneous intermediate 
to high signal intensity, clearly distinguishable from the transition and central zones. 
PCa can appear as an area of low signal intensity. High-grade tumors, with a Gleason 
grade 4 or 5, usually present with a lower signal intensity (11). Low-grade tumors, with 
a Gleason grade 2 or 3, can present as T2-isointense areas, or even as non-focal 
mildly hypointense abnormalities. Non-malignant conditions, such as (post-biopsy) 
hematomas, (granulomatous) prostatitis, scar tissue, atrophy, post-radiation changes 
and hormonal therapy effects, also manifest as T2-hypointense lesions in the 
peripheral zone (12,13).
 The transition zone is characterized by low signal intensity on T2-weighted 
images, frequently intermingled by round, well-circumscribed heterogeneous BPH 
nodules with a mixed heterogeneous high and low signal intensity, in a pattern 
described as ‘organized chaos’. The diagnosis of PCa in the transitions zone imposes 
an even greater challenge than in the peripheral zone. If there is an ill-defined 
homogeneous T2-hypointense focal lesion (‘erased charcoal drawing sign’), a lesion 
with spiculated or undefined margins, an anteriorly located lesion with a lenticular or 
fusiform shape, loss of the T2-hypointense contour of BPH nodules, loss of definition 
of the pseudo-capsule, or signs of urethral invasion, PCa might be present. 
 Next to high-resolution T2-weighted imaging, additional functional and metabolic 
techniques, such as dynamic contrast-enhanced MRI (DCE-MRI)(14) and diffu-
sion-weighted imaging (DWI)(15) has made MRI an even more powerful modality in 
the detection and localization of PCa. DCE-MRI improves the sensitivity in PCa 
detection (16-18) and DWI (19-22) adds specificity in characterization of PCa. For 
these reasons, a group of prostate MRI experts of the European Society of Urogenital 
Radiology (ESUR) recommends a multi-parametric approach, combining high-reso-
lution T2-weighted images with at least two functional MR techniques for improving 
detection and characterization of PCa (23). At this moment, multi-parametric MRI is 
the most sensitive and specific imaging technique for localizing prostate cancer (24).
 DCE-MR imaging is most commonly based on fast axial T1-weighted sequences 
which are repeatedly acquired before, during and after IV bolus injection (2–4 mL/s) 
14
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of a gadolinium-based contrast medium, encompassing the whole prostate gland 
and seminal vesicles, with a temporal resolution preferably lower than 15 s per 
acquisition (23). It is a functional MR imaging technique that shows the dynamic 
uptake and washout of the contrast agent to exploit the typical pharmacokinetic 
properties of normal and tumor tissue (Figure 2B).
 In most of the neoplastic conditions, PCa included, angiogenesis is induced by 
secretion of vascular growth factors in reaction to local hypoxia or lack of nutrients 
(25). An increase in tumor vascularity leads to an enhancement pattern with peaks 
earlier and higher than those of the normal surrounding tissue, combined also with 
early and pronounced contrast media washout (25,26).
 Other benign conditions such as prostatitis in the peripheral zone and BPH in the 
central gland also lead to changes in the enhancement pattern. Therefore, PCa is 
hard to detect with DCE-MRI alone. 
 It has been shown that DCE is significantly better than conventional T2-weighted 
imaging alone in the localization of tumor foci (27,28), and that it increases the 
accuracy of less experienced radiologists in the detection of extracapsular extension 
and seminal vesicle involvement (29). Because of this, the use of DCE is definitely 
well indicated, and is a fundamental part of multi-parametric prostate MR imaging.
 In diffusion-weighted imaging (DWI) the random movement of water molecules 
in tissue is shown. In an environment of totally unrestricted diffusion, the movement 
of water molecules is completely random, constituting a phenomenon known as 
Brownian movement, or ‘free diffusion’. Restricted diffusion is seen in tissues with a 
high cellular density and intact cell membranes. Tissue types associated with 
restricted diffusion comprise cancer, abscess, cytotoxic edema and fibrosis (30).
 On diffusion-weighted images areas with restricted diffusion have a hyperintense 
signal (Figure 2D). The sensitivity of DWI to water movement is variable, depending 
on the MR field strength and on the time/amplitude relation of the movement-encod-
ing gradient, also known as b-value. For local prostate imaging, DWI should be 
performed with at least 2 b-values, including a low b-value of 50 – 100 s/mm2 and a 
higher b-value of 500–1000 s/mm2. Based on the diffusion-weighted images, a 
so-called apparent diffusion coefficient (ADC) map can be calculated (Figure 2C). 
ADC is measured in millimeter per second squared (mm/s2), and provides quantitative 
information that is inversely proportional to the degree of diffusion restriction. Low 
ADC values, which are hypointense on the ADC map, represent tissue with restricted 
diffusion. There is a significant overlap; ADC values of prostatitis are lower than 
normal prostate tissue, and significantly higher than low- and high-grade PCa (21,22). 
PCa is histologically characterized by a higher cell density and a higher nucleus/
cytoplasm ratio than the surrounding normal prostate tissue, with substitution of the 
glandular parenchyma by tumor cells. This causes a marked reduction in the ADC 
values relative to the normal prostate (15).
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Biopsy
As mentioned earlier, random systematic TRUS-guided biopsies have relatively low 
detection rates and are affected by undersampling and underscoring of PCa (9,10). 
As multi-parametric MRI is the most sensitive and specific imaging technique for 
localizing prostate cancer (24), it can be used to target biopsies towards regions 
previously determined to be suspicious for cancer. 
 MRI-guided biopsy can be performed in three different ways and every method 
has its own benefits and limitations. For every of these three methods counts that the 
multi-parametric MRI for tumor detection and localization and the biopsy procedure 
need to be performed in two different sessions, because image post-processing and 
Figure 2  Typical example of multi-parametric MR imaging of a 64 year old man with a PSA 
level of 13 ng/mL and 1 negative TRUS biopsy session, showing a typical case of a peripheral 
zone tumor (encircled). With MR-guided biopsy a GS 4+4=8 was found. A. Axial T2-weighted 
image. B. Axial DCE image. C. Axial ADC map. D. Axial DWI with b=1400 (calculated).
A
C
B
D
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accurate localization require time. At the moment there is no consensus as to which 
is the best method; however, MRI-targeted biopsies result in fewer biopsies in fewer 
men, with a decreased amount of clinically insignificant cancers compared to 
standard TRUS-guided biopsy (31).
 The first method is visual targeting, where the urologist performs a TRUS-guided 
biopsy and aims for specific cancer-suspicious regions (CSR) previously detected on 
MR images. An advantage of this method is that it needs no additional equipment; 
however, especially anterior and apical CSRs could be hard to identify on ultrasound 
images, and can therefore be missed. 
 The second method is by using rigid or elastic registration or fusion software, 
where MR images are fused with real-time TRUS images. The crucial factor in this 
method is accurate fusion of the images, which can be affected by, for example, 
prostate deformation or patient movement. 
 The third method is completely MRI-guided, so the complete biopsy is performed 
in the MR scanner itself. A needle guide is inserted in the rectum and the radiologist 
has to manually adjust the needle guide to aim to the CSR. This procedure needs a 
trained radiologist and takes more time than a systematic TRUS-guided biopsy. For 
these reasons MR-compatible robots for needle placement have been developed 
(32,33). The first results are promising and in the future these robots might also play 
a role in MRI-guided therapies as focal laser ablation and cryoablation. 
Treatment of primary prostate cancer
At present, treatment choice for primary PCa patients lies between active surveillance 
(AS) and whole gland therapies, such as radical prostatectomy (RP) or radiotherapy 
(RT), depending on the stage, volume and aggressiveness of the PCa and the age 
and health status of the patient. Radical prostate treatments, i.e. RP and RT are the 
current gold standard.
 During AS the prostate cancer is carefully monitored for signs of progression. 
Surveillance is performed by periodic digital rectal examinations, PSA level 
measurements and (systematic) prostate biopsies. If these tests indicate cancer 
growth or when symptoms develop, whole gland treatment might be warranted. In 
general, this type of treatment is only suitable for men with low-risk PCa (PSA≤10 ng/
mL, clinical stage ≤T2, GS≤6) or in older men with limited life expectancy (34). 
 During a RP the entire prostate gland is surgically removed. This treatment can 
be performed by an open procedure with a large incision through the lower abdomen; 
laparoscopic, or with robot-assistance. Radiotherapy can be applied in different 
forms: external beam radiation therapy (EBRT) or by brachytherapy. During EBRT 
an external beam of ionizing radiation is focused on the prostate. Sometimes a few 
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gold markers are inserted into the prostate to optimize treatment planning. During 
brachytherapy radioactive seeds are permanently implanted in the prostate. 
 However, whole gland treatments come with a morbidity rate and decreased 
quality of life (35,36). For instance, 2 years after treatment, 3.2–9.6% of these patients 
experiences urinary leakage and 56–78.8% suffers from erectile dysfunction (35,36). 
In addition, these treatments represent a high burden for patients, as they require 
hospital admission for several days (RP) or up to 30 visits to the hospital (RT).
Focal therapy
Focal therapy is an emerging alternative treatment option, which offers great hopes 
in terms of cancer control and decreased morbidity for localized PCa. The challenge 
of focal therapy is to treat only localized tumors, sparing the rest of the prostate, 
especially near the neurovascular bundles and the urethral sphincter, to minimize 
potential morbidity (37). The current definition for focal therapy as determined by an 
international group of experts is “ablation of the dominant or index lesion only” (38). 
Despite this, different varieties of focal therapy are described in literature: hemi- 
ablation, (i.e. treatment of the tumor affected lateralized hemisphere of the prostate), 
hockey stick ablation (i.e. hemi-ablation of the prostate plus one half of the contra 
lateral hemisphere) and targeted focal therapy (i.e. only the tumor itself is treated).
 The focal therapy concept remains controversial because PCa is a multifocal 
disease. However, 13–33% of patients have 1 PCa lesion and would be eligible for 
focal therapy (39). Consistent with the “index lesion theory”, indicating that most 
tumors other than the index cancer, may not be of clinical significance, even more 
patients would be suitable (40).
 Various minimal invasive techniques such as cryoablation, focal laser ablation 
(FLA), irreversible electroporation (IRE), high intensity focused ultrasound (HIFU), 
brachytherapy and photodynamic therapy (PDT) have been used to perform focal 
therapy in PCa patients (41-48). All these techniques have their own characteristics 
and are still evolving. There is no consensus yet which treatment method is the best 
for focal therapy.
 To be able to perform focal therapy, accurate and adequate image guidance is a 
prerequisite. MR imaging provides two key advantages for an effective focal treatment 
over other imaging modalities as ultrasound (US) or computed tomography (CT). 
First, its excellent soft tissue contrast and multi-planar imaging capabilities allow for 
clear visualization of the tumor and for accurate thermal applicator placement into the 
lesion. Second, MR thermometry allows to measure in real-time the spatial distribution 
of the temperature in tissue, which is important to estimate boundaries of irreversible 
tissue necrosis. For these reasons, MR imaging is perfectly suited to use for image 
18
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guidance during focal therapy, because it can be used to localize the tumor, target it 
with probes, monitor and control the ablation procedure in real-time and to map 
tissue temperature.
 Focal cryoablation can also serve as an alternative salvage treatment option for 
patients with local recurrent disease after RT (49,50). Local cancer control can be 
obtained with a reduced risk on treatment-related comorbidities. Again, accurate 
image guidance is of incremental value to enable focal treatment. MR imaging 
enables accurate lesion targeting and treatment monitoring during cryoablation. Ice 
ball growth can be monitored in real time and in multiple planes, such that damage 
to adjacent critical structures as the rectal wall can be minimized.(43) 
Local recurrence
PCa recurrence after previous radiotherapy is very frequent, a biochemical failure is 
affecting 10–60% of the patients (51,52) Currently, a rise in PSA level is the only major 
indicator for PCa recurrence, because both DRE and TRUS are of diminished value 
because of the difficulty in differentiation between recurrent disease or fibrotic changes. 
 Multi-parametric MRI is able to accurately diagnose recurrent PCa after RT 
(53,54). Local recurrence after RT appears often at the same location as the initial 
tumor (55). The detection of local recurrence can be difficult on the T2-weighted 
images alone. It may present itself as a lesion with a signal intensity lower than that of 
the surrounding normal prostate tissue; however, it can be unapparent as well, 
because of decreased contrast between benign irradiated tissue and tumor 
recurrence, and eventually by decreased image quality as a result of the implanted 
gold markers or radioactive brachyseeds. However, the latter will influence the quality 
of DWI in particular. On diffusion-weighted images restricted diffusion might be seen, 
represented as areas with low ADC values and/or high signal intensity on the high 
b-value images. On the DCE images recurrent tumor can show early enhancement 
and early washout. Evaluation of extracapsular extension might be hindered by 
RT-induced irregularity of the capsule (56). 
 Current treatment options are salvage radical prostatectomy (SRP) or andro-
gen-deprivation therapy (ADT). SRP has a curative intent, but is technically 
challenging, because of radiation-induced fibrosis and shrinkage of the prostate. 
This results in high rates of urinary incontinence and rectal injury (57,58) severely 
affecting the quality of life of patients. Surgery is not eligible in most of the patients 
because of their age and comorbidities. In that case ADT can be an alternative. 
However, ADT is a palliative treatment option with only temporarily effect, which can 
lead to an increased risk of cardiovascular mortality and skeletal fracture and a 
decreased quality of life (59,60).
19
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Focal cryoablation can also serve as an alternative salvage treatment option for 
patients with local recurrent disease after RT (49,50). Local cancer control can be 
obtained with a reduced risk on treatment-related comorbidities. Again, accurate 
image guidance is of incremental value to enable focal treatment. MR imaging 
enables accurate lesion targeting and treatment monitoring during cryoablation. Ice 
ball growth can be monitored in real time and in multiple planes, such that damage 
to adjacent critical structures as the rectal wall can be minimized(43). 
Aim and outline 
Focal therapy as treatment option for localized (recurrent) PCa is an increasingly 
popular and rapidly developing area. With multiparametric MR imaging we are able 
to accurately detect and localize prostate cancer. Next to this, MRI-guidance enables 
accurate tumor targeting, treatment monitoring and to map the tissue temperature in 
real-time. The purpose of this thesis is to develop and optimize MRI-guided focal 
therapy in patients with localized (recurrent) prostate cancer. 
 This thesis consists out of 11 chapters. In Chapter 2 the accuracy and speed of 
a novel robotic technique as an aid to perform MRI-guided prostate biopsies on 
patients with cancer suspicious regions are evaluated. From 13 consecutive biopsy 
procedures, the targeting error, biopsy error and target displacement are calculated to 
evaluate the accuracy. The time is recorded to evaluate manipulation and procedure time.
 The purpose of Chapter 3 is to assess the feasibility of a 2nd generation 
MR-compatible, remote-controlled manipulator as an aid to perform MRI-guided 
transrectal prostate biopsy in males with suspicion of prostate cancer. Twenty patients 
undergo MRI-guided biopsy with the aid of the remote-controlled manipulator. 
Complications are classified according to the modified Clavien system for reporting 
surgical complications. For evaluation of the workflow, procedure- and manipulation 
times are recorded. 
 The aim of Chapter 4 is to evaluate different MRI-guided therapy options and to 
investigate their feasibility for focal therapy in prostate cancer patients. It discusses 
cryoablation, laser ablation, (high intensity) focused ultrasound, radiofrequency 
ablation, microwave ablation and low- and high-dose-rate brachytherapy as possible 
options for MRI-guided focal therapy of the prostate.
 The purpose of Chapter 5 is to correlate T1-weighted MR image contrast around 
an iceball during MRI-guided cryoablation with temperature. First the normalized 
signal intensity was correlated with the temperature in a phantom study. Hereafter the 
same T1-weighted imaging sequence was acquired in ten consecutive patients to 
assess the in vivo appearance of an iceball during MRI-guided focal cryoablation 
treatment. The results and clinical implications are discussed. 
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The aim of Chapter 6 is to assess the feasibility of MRI-guided focal cryoablation 
in patients with locally recurrent prostate cancer after radiotherapy. It describes the 
(intra-procedural)complications and preliminary results of the first ten patients that 
were treated in our institution. 
 In Chapter 7 the short term (12 months) follow-up results after MRI-guided 
cryoablation for 41 patients are presented. Feasibility and adverse events were 
reported with rates and description of adverse events. Surgical complications were 
classified according to the Clavien system. Validated questionnaires were used to 
observe functional outcomes and quality of life before therapy and after 6 and 12 
months. Cancer control was defined as no biochemical failure according to Phoe-
nix-criteria and no other clinical, radiological or histopathological evidence for local 
or metastatic disease.
 The aim of Chapter 8 is to correlate treatment effects of MRI-guided focal laser 
ablation in patients with newly diagnosed prostate cancer with MR imaging using 
prostatectomy as standard of reference. Three weeks before their radical prostatectomy, 
five patients underwent MRI-guided focal laser ablation as extra treatment. Damage 
estimation maps, based on MR thermometry imaging, and T1-weighted contrast- 
enhanced images acquired directly after laser ablation are compared with the histo-
pathology results. 
 Chapter 9 provides a general discussion and the conclusions of this thesis. In 
the end some future perspectives are considered.
 Chapter 10 provides a summary of this thesis and in Chapter 11 a Dutch 
translation of this summary is presented.
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Abstract
Objectives:
To evaluate the accuracy and speed of a novel robotic technique as an aid to perform 
magnetic resonance image (MRI)-guided prostate biopsies on patients with cancer 
suspicious regions.
Methods: 
A pneumatic controlled MR-compatible manipulator with 5 degrees of freedom was 
developed in-house to guide biopsies under real-time imaging. From 13 consecutive 
biopsy procedures, the targeting error, biopsy error and target displacement were 
calculated to evaluate the accuracy. The time was recorded to evaluate manipulation 
and procedure time.
Results: 
The robotic and manual techniques demonstrated comparable results regarding 
mean targeting error (5.7 vs 5.8 mm, respectively) and mean target displacement (6.6 
vs 6.0 mm, respectively). The mean biopsy error was larger (6.5 vs 4.4 mm) when 
using the robotic technique, although not significant. Mean procedure and manipulation 
time were 76 min and 6 min, respectively using the robotic technique and 61 and 
8 min with the manual technique.
Conclusions: 
Although comparable results regarding accuracy and speed were found, the extended 
technical effort of the robotic technique make the manual technique – currently – 
more suitable to perform MRI-guided biopsies. Furthermore, this study provided a 
better insight in displacement of the target during in vivo biopsy procedures.
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Introduction 
The detection rate of prostate cancer (PCa) in men with elevated and/or rising prostate 
specific antigen (PSA) after negative transrectal ultrasound (TRUS)-guided biopsy 
sessions is poor. Hambrock et al. found a cancer detection rate of 59% for magnetic 
resonance imaging (MRI)-guided biopsies, in men with an elevated PSA and multiple 
previous negative TRUS-guided biopsy sessions. This is an improvement when 
compared to 8 to 12-core TRUS-guided biopsy schemes with a detection rate around 
17% in patients with ≥1 previous negative TRUS-guided biopsy (1-3). Nevertheless, 
MRI-guided biopsy is unpleasant for the patient and time-consuming for the 
radiologist. For these reasons an in-house pneumatically actuated MR-compatible 
robot was developed where needle-guide direction can be controlled in real-time 
inside the controller room (Figure 1) (4). Consequently, the patient remains inside the 
scanner bore. This may decrease procedure time, enhance patient comfort and 
improve needle-guide positioning.
 Eighty-percent of the tumors with a volume larger than 0.5 cm3 (diameter=1.0 cm) 
are likely to be clinically significant (5). Therefore, it is desirable to have a technique 
with a biopsy error smaller than 5 mm. Different factors, such as needle-guide 
positioning, patient and prostate motion, and tissue deformation influence the 
accuracy of needle positioning (6-8). Consequently, the needle does not always 
reach the cancer suspicious region (CSR).
 In a phantom study the new robotic technique demonstrated a short manipulation 
time of 5 min (range 3–8 min) and a high accuracy of 3.0 mm (range 0–5.6 mm) for 
needle positioning (4). Yakar et al. demonstrated that it is technical feasible to perform 
Figure 1  A: The robot with (1) the needle guide, (2) safety mechanism with the suction cup, 
(3) tapping mechanism to introduce the needle guide, (4) pneumatic motor, (5) tubings to the 
motors, (6) ground plate, (7) angulation rail. B: Set-up of a patient with the robotic technique on 
the table of the MR system.
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transrectal prostate biopsies using the novel robotic technique (n=10) (9). To evaluate 
and optimize the biopsy procedure in the future, it is necessary to identify and quantify 
the cause of the biopsy error. Therefore, the purpose of this study was to evaluate the 
accuracy and speed of the novel robotic technique as an aid to perform MRI-guided 
biopsy on patients with CSRs.
Materials and Methods
Patients
This study was approved by the ethics review board and written informed consent 
was obtained from all patients who were biopsied with the robotic technique. From 
February to September 2010, 13 consecutive patients with an elevated PSA (>4 ng/
mL) and at least one negative TRUS-guided biopsy session were included. Patient 
were included in the robotic patient population based on their willingness. The manual 
patient population was matched to the robotic population. Prior to the MRI-guided 
biopsy, patients received a 3T (Magnetom TRIO, Siemens, Germany) multi-parametric 
MRI examination of the prostate for identification of possible CSRs. T2-weighted 
(T2-w) images in three orthogonal planes, transversal diffusion weighted images 
(DWI) and dynamic contrast-enhanced (DCE)-MR images (Table 1) were obtained 
during and after injection of 15 ml gadopentetate dimeglumine with a power injector 
(Guerbet, Gorinchem, Netherlands). To evaluate the CSR for clinical significance, the 
criteria for MRI-guided biopsy reported by Hambrock et al. were applied (3).
 CSRs were determined in consensus by 2 readers with at least 6 years of 
experience in prostate MR reading. From each CSR the volume (in cc) was determined 
on the MR images, assuming that the lesions were ellipsoids.
MRI-guided biopsy
MRI-guided biopsy were performed within 12 weeks after the diagnostic multi-para-
metric MR examination. Antibiotic prophylaxis was given with 500 mg ciprofloxacin in 
the morning and evening for three consecutive days, starting the day before biopsy. 
A schematic representation of the steps taken to perform a biopsy is illustrated in the 
flow chart (Figure 2). 
 A needle-guide filled with gadolinium-doped water was inserted in the rectum of 
the patient. Subsequently, the needle-guide was mounted to the robotic or manual 
device (Step 1). The MR imaging protocol (Step 2) for target selection and to navigate 
on during the biopsy procedure is shown in Table 1.
 Targets were selected (Step 3) on these images based on the CSRs found in the 
diagnostic MRI examination. Manipulation of the needle-guide was done using either 
the robotic or manual technique (Step 5). After correct alignment of the needle-guide 
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the insertion depth of the needle was measured on a transversal true-FISP (TRUFI) 
image (Table 1). The patient was slid out the gantry to insert the biopsy needle 
manually (titanium 18-gauge, fully automatic, core-needle, double-shot biopsy gun 
with needle length of 175, sampling length of 17 mm (Invivo, Schwerin, Germany).
 A T2-w 3D volumetric gradient-echo (first two procedures with the robotic 
technique) or a T2-w 3D volumetric spin-echo image (all other patients) was acquired 
with the needle inserted (Step 7). This was the same 3D volumetric image (Table 1) 
as acquired in step 2. When the needle was in correct position, confirmed on the 
control images, another target could be targeted (Steps 3–8) or the patient was 
removed from the MR table (Step 9).
Needle-guide positioning: robotic technique
The robotic system has five degrees of freedom: translations in three directions (an-
terior-posterior, inferior-superior, lateral) and rotations in two directions (inferior-supe-
rior, lateral). The angle of the needle-guide with the main magnetic field could range 
from 30° to 55° in the inferior-superior direction and plus or minus 26° in the lateral 
direction (4).
 With a simple graphical user interface the direction of the needle-guide can be 
adjusted (9). A software package (Interactive Front End (IFE); Siemens Corporate 
Research, Baltimore (MD), USA) was used to orient and direct the needle-guide in the 
desired direction (Step 5) under real-time image guidance (Table 1). Manipulation of 
images and relevant controls can be performed during imaging which allows 
interactive slice positioning for path planning and real-time monitoring (10,11).
Needle-guide positioning: manual technique
Transversal and sagittal TRUFI images (Table 1) through the needle-guide were 
acquired to determine needle-guide direction. The patient was withdrawn from the 
Figure 2  Flow chart of the biopsy procedure for both the robotic and manual techniques. Scan 
plane adjustments were only performed with the IFE software (step 4) when using the robotic 
technique.
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scanner bore and the radiologist manually adjusted the biopsy device to point the 
needle-guide towards the target. To confirm correct positioning of the needle guide 
sagittal and transversal TRUFI images were acquired through the needle-guide again. 
These actions were repeated until the needle-guide was in correct position (12). 
 Total procedure time and manipulation time were recorded for both the robotic 
and manual techniques.
Measurements
Motion and deformation of the prostate may occur during the biopsy procedure. This 
will have effect on the position of the target. Since targeting of the CSR in both 
methods was done on the images acquired in Step 2, which do not take deformation 
and motion into account, it is important to distinguish between targeting and biopsy 
error (Figure 3).
Table 1  Imaging protocol with sequence specifications. 
Protocol Sequence TA
(min:s)
TR 
(ms)
TE
(ms)
FA
(°)
Voxel size  
(mm×mm×mm)
Diagnostic MRI
T2WI Axial
Coronal
Sagittal
3:22-4:43 4480-4950 103-110 120 0.6x0.6x3.0
DWI Axial 3:08 2300-2500 61-64 2.0x2.0x4.0
DCE 3D GRE 2:43 32 1.47 10 1.8x1.8x4.0
Biopsy
T2WI Axial 3:26 3620 103 120 0.8x0.8x4.0
DWI Axial 2:06 2000 67 1.8x1.8x4.0
TRUFI
(manual)
Axial
Sagittal
0:075
0:089
4.48 2.24 70 1.1x1.1x3.0
TRUFI
(robot)
Axial
Coronal
Sagittal
0.9s/slice 894 2.3 60 1.6x1.6x5.0
T1WI 3D-GRE* 2:20 4.5 2.2 43 1.0x1.0x1.0
T2WI 3D-SE 2:36 1000 102 100 1.0x1.0x1.0
* The initial two volumetric images (2/13) were GRE sequences (first 2 procedures using the robot)
T2WI= T2-weighted MR imaging, DWI= Diffusion-weighted imaging, DCE= Dynamic contrast-en-
hanced imaging, TRUFI= true-FISP, T1WI= T1-weighted MR imaging, 3D= 3 dimensional, GRE= Gra-
dient echo, SE= Spin echo, TA = acquisition time, TR= repetition time, TE= echo time, FA= flip angle
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Targeting error (ε) 
The targeting error is defined as the normal (shortest) distance from the needle 
trajectory to the original target location (Figure 3). This error does not take tissue 
deformation and patient motion into consideration. This error is a measure for 
needle-guide positioning towards the intended target.
Biopsy error (δ) 
The biopsy error is defined as the normal distance from the needle to the transformed 
target location (the actual target location after needle insertion). The coordinates of 
the transformed target are corrected for tissue deformation, as well as patient and 
prostate motion. The transformed target coordinates were calculated by adding the 
target displacement vector to the original target coordinates.
Target displacement (8) 
The target displacement vector is defined by the distance and angle between the 
original and transformed target location. The target displacement (φ) is the length of 
this vector. The 3D volumetric images made before (Step 2) and after needle insertion 
(Step 7) were used to determine the target displacement vector. In these images 
identical anatomical landmarks around the target (mean 13.7 mm; range 2.3 –48.4 
mm) were manually selected with the aid of an open source fusion package (13). 
Figure 3  Representation of the needle inside the prostate with target (T) and the transformed 
target location (T’), illustrating targeting error (ε), target displacement (φ) and biopsy error (δ).
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Calcifications, benign prostate hyperplasia (BPH) nodules, the verumontanum and 
the urethra were used as anatomical landmarks. Coordinates of these anatomical 
landmarks (≥5) were used to create a 3D vector field. The arrows represent the direction 
and distance of displacement of anatomical landmarks (Figure 4). The mean vector 
of this vector field is a quantitative measure for localized target displacement, since 
anatomical landmarks around the target were selected.
 To calculate the targeting and biopsy error the needle trajectory was determined 
by fitting a line through multiple points (≥8) within the needle artifact using linear 
regression in 3D-space. These points were obtained from the 3D volumetric MR 
images obtained in Step 7. Target coordinates (CSRs) were obtained from the T2-w 
and DW images acquired in Step 2. The angle between needle trajectory and target 
displacement direction was calculated in order to see whether the target moved 
along the needle trajectory or in a random direction (Figure 5).
Figure 4  3D vector field: The blue arrows represent the direction and displacement of the 
anatomical landmarks. The red arrow is the mean vector representing target displacement. 
Furthermore, the needle trajectory (black line), targeting error (ε), original target (T), biopsy 
error (δ) and transformed target (T′) are shown.
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Figure 5  A: Axial TRUFI image through the needle guide. B: Axial TRUFI image through the 
needle guide after needle insertion in the prostate.
Table 2  Patient characteristics and biopsy results for both techniques
Patient characteristics and biopsy results Robotic Manual
Number of patients 8 5
Number of needle placements 19 13
Median needle positions per patient 1.5 
(range 1 – 3)
2 
(range 1 – 4)
Mean PSA (ng/mL) 15 
(range 8 – 28)
14 
(range 7 – 19)
Mean prostate volume (cc) 67 
(range 44 – 98)
72 
(range 49 – 100)
Median number of repeated negative 
TRUS-guided biopsy sessions
2 
(range 1 – 4)
2 
(range 1 – 4)
Median CSR volume on MR images (cc) 0.85 
(range 0.38 –1.61)
0.91 
(range 0.6 – 3.19)
Histopathological findings
Non-malignant
Prostatitis
Cancer
3
3
2
2
2
1
a. b.
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Statistical analysis
Two-tailed independent t-tests were performed to determine whether there were 
significant differences between the robotic and manual techniques for targeting error, 
biopsy error, target displacement, procedure and manipulation time. Differences 
were considered to be significant at p<.05. Statistical analysis were performed with 
SPSS, version 16.0.01 (Chicago, Illinois).
Results
In total, 13 patients with 32 needle positions were analyzed. Table 2 describes the 
patient characteristics and biopsy results for both techniques. Since the majority of 
previous negative TRUS-guided biopsy sessions had been performed outside our 
institution, information on the number of cores was not available for most patients.
Accuracy
The mean targeting error for both the robotic and manual techniques was almost 
similar (5.7 vs 5.8 mm respectively, p=0.928) (Figure 6). The mean biopsy error was 
less (4.4 vs 6.5 mm) with the manual technique compared to the robotic technique 
(p=0.054). Target displacement was larger with the robotic technique (6.6 vs 6.0 mm, 
p=0.439).
Figure 6  Histogram showing the mean targeting error, biopsy error and target displacement 
for both the robotic and manual techniques. The error bars represent the standard deviation.
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Direction of target displacement 
The mean angle between needle trajectory and target displacement direction for the 
robotic and manual techniques was 36.7° (range 4.0–82.2°) and 37.6° (range 7.7–73.3°), 
respectively. 
Time
The mean time to perform a biopsy procedure using the robotic technique was 76 min 
(range 60–100 min) and 61 min (range 52–64 min) with the manual technique. The total 
procedure time includes the extra time to acquire the 3D volumetric images (2:36 min 
each). The mean manipulation time to move from target to target was 6 min (range 
3–11 min) with the robotic technique and 8 min (range 5–11 min) with the manual 
technique. The differences in manipulation time and procedure time between both 
techniques were not significant.
Discussion
The robotic and manual techniques demonstrated comparable results regarding 
targeting error and target displacement. The biopsy error was larger when using the 
robotic technique, however not statistically significant. The robotic technique 
prevented the need of moving the patient in and out of the scanner bore for 
manipulation and imaging of the needle-guide. Most of the target displacement 
found in our study was in the direction of the needle trajectory. 
 Several robots for transperineal seed delivery in brachytherapy have been 
described in literature (14-17). The robotic and manual techniques for transrectal 
biopsies demonstrated a larger targeting error (5.7 and 5 mm respectively) compared 
to other robotic techniques. Muntener et al. found a targeting error of 2.02 mm (range 
0.86–3.18 mm) with their robot in a canine model (16). Zangos et al. describe a 
transgluteal approach for prostate biopsy with a targeting error of 0.9 mm (range, 
0.3–1.6 mm) (18). The targeting error, biopsy error and target displacement for a 
transrectal biopsy device were 2.2 mm (range 0.5–5.7 mm), 5.1 mm (range 1.6–11.0 
mm) and 5.4 mm (range 1.6–11.1 mm) respectively. Although the targeting error was 
less compared to our results, the biopsy error and target displacement were in 
concordance with our results (19). 
 MRI-TRUS-fusion biopsy may be an alternative to MRI-guided biopsy in the 
future because its availability and is probably less expensive. However, initial results 
show registration errors around three millimeter in phantoms and patients (20-23). In 
addition to this error is the targeting error and tissue deformation which together 
determine the ability to sample a CSR. 
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The anatomical landmarks chosen in the MR images to determine target displacement 
were selected manually. This may have introduced an error, since it is difficult to 
select exactly the same position. Automatic registration would be an alternative to 
diminish this error. However, automatic registration is difficult and introduces errors 
as well (15). Furthermore, the images that need to be registered are different in the 
area of the target, because of the presence of the needle, causing a line shape void 
in the area where best registration is needed. 
 The biopsy procedures with the robotic and manual techniques were not 
performed by the same radiologist. To overcome the limitation of inter-variability, the 
performing physician of each procedure performed the biopsy session in consensus 
with the first author who attended all sessions. Despite the fact that patient selection 
for each technique was not randomly chosen, both groups had similar patient 
 characteristics (Table 2). The number of cores taken during TRUS-guided biopsy was 
not available for most patients in both groups.
 In the first patient a gradient-echo sequence was used to determine needle 
trajectory and target displacement. The needle artifact size was acceptable, varying 
from 3.5 mm to 4.5 mm. In the second patient, the angle of the needle with the static 
magnetic field was larger. As a result, the artifact size of the needle increased to 8.5 mm. 
Therefore, we decided to use a 3D spin-echo sequence in which the signal void 
around the needle was less influenced by distortions of the magnetic field. Needle 
artifact size now varied from 3.8 to 4.7 mm. 
 The quantitative method described to determine target displacement cannot 
discriminate between patient motion, prostate motion and tissue deformation. However, 
our results demonstrated that most target displacement was in the direction of the 
needle trajectory suggesting that most of the target displacement was caused by 
needle insertion. 
 Hambrock et al. found a median imaging time of 35 min for a MRI-guided biopsy 
procedure (24). In our study, we reported the total procedure times (including patient 
preparation) for the robotic and manual techniques. Although manipulation time was 
shorter when using the robotic technique, the total procedure time was longer 
compared to the manual technique. Positioning of the patient was a precise and 
time-consuming process. In case of incorrect positioning the whole set-up did not fit 
inside the scanner bore, or the range of motion of the robotic technique was impaired. 
Furthermore, a connection with the IFE software was necessary for real-time image 
guidance. Even for small adjustments in needle-guide direction, a interaction with the 
IFE was necessary including manual selection of the correct slice direction through 
the needle guide. Furthermore, some actions were only possible from behind the 
MR-console (e.g. measurement tool); the operator had to switch constantly between 
MR console and IFE monitor during the procedure. Altogether this led to an extension 
of the procedure time. 
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Image registration during the biopsy procedure can correct for target displacement and 
may attribute to reduce the biopsy error (25). Nevertheless, image registration is often 
a time consuming process. Furthermore, our results suggested that movement of the 
target was mainly caused by needle insertion. Image registration would not correct 
for prostate motion due to needle insertion. Deformation models of the prostate to 
predict tissue deformation due to needle insertion may help to overcome this problem 
(26). Other alternatives are different techniques for needle insertion, such as rotating 
needles and tapping devices (27-30).
 Promising treatment types in the MR-scanner such as cryosurgery (31) and focal 
laser ablation (32) are now under investigation. Major advantages of treatment in the 
MR scanner are the ability of soft tissue imaging and monitoring (for example 
temperature mapping) (33). Robotics will play an important role in the future during 
treatment in the MR since accurate needle placement is required. 
 In spite of the fact that the results are comparable regarding accuracy and speed, 
the larger biopsy error and the extended technical effort of the robotic technique make 
the manual technique – currently – more suitable to perform MRI-guided biopsy. 
Furthermore, this study provided a better insight in displacement of the target during 
in-vivo biopsy procedures.
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Abstract
Objectives:
To assess the feasibility of a 2nd generation MR-compatible, remote-controlled 
manipulator (RCM) as an aid to perform MRI-guided transrectal prostate biopsy in 
males with suspicion of prostate cancer (PCa).
Methods: 
This prospective phase I study was approved by the local ethical committee and 
written informed consent was obtained from each patient. Twenty patients with ≥1 
cancer suspicious region (CSR) with a PI-RADS score of ≥3 detected on the diagnostic 
multi-parametric MRI and no prior prostate treatment underwent MRI-guided biopsy 
with the aid of the RCM. Complications were classified according to the modified 
Clavien system for reporting surgical complications. For evaluation of the workflow, 
procedure- and manipulation times were recorded.
Results: 
All CSRs (n=20) were reachable with the MR-compatible RCM and the cancer 
detection rate was 70%. The median procedure time was 36:44 minutes (range, 23 - 
61 minutes) and the median manipulation time for needle guide movement was 
5:48 minutes (range, 1:15 - 18:35 minutes). Two Clavien grade 1 complications were 
reported.
Conclusions: 
It is feasible and safe to perform transrectal MRI-guided prostate biopsy using a 
MR-compatible RCM as an aid. It is a fast and efficient way to biopsy suspicious 
prostate lesions with a minimum number of biopsies per patient.
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Introduction 
Men with a suspicion of prostate cancer (PCa), due to an elevated prostate specific 
antigen (PSA) and/or an anomalous digital rectal examination, undergo random 
systematic transrectal ultrasound (TRUS) guided biopsies to detect PCa. However, 
these biopsies are affected by underscoring and undersampling of PCa and have 
relatively low detection rates (22 -42 %) (1-3). 
 Currently, multi-parametric magnetic resonance imaging (MRI) is the most sensitive 
and specific imaging technique for localizing PCa (4). Earlier reports indicated higher 
detection rates for clinically significant PCa with multi-parametric MRI and MRI-guided 
biopsies, which were previously missed with systematic TRUS-guided biopsies (5,6). 
Recently, it has been shown that MRI-guided biopsies resulted in fewer biopsies per 
patient compared with standard TRUS biopsy, and a decreased detection rate of 
clinically insignificant cancers (7,8).
 Nevertheless, there are some limitations associated with in-bore MRI-guided 
prostate biopsies. It can be time-consuming, site-experience with multi-parametric 
MRI and a trained prostate radiologist are needed. The majority of the procedure time 
in MRI-guided prostate biopsy is lost during device manipulation. To facilitate correct 
alignment of the needle guide with the target lesion, the patient is repeatedly moved 
in and out of the MR scanner for device manipulation. To simplify and improve the 
process of needle placement, MR-compatible manipulators have been developed 
(9,10). 
 The purpose of this phase I study was to assess the feasibility of a 2nd generation 
MR-compatible manipulator as an aid to perform transrectal prostate biopsy in males 
with rising PSA and at least one suspicious lesion visible on the diagnostic multi- 
parametric MRI.
Materials and Methods
Patients
This prospective phase I study was approved by the local ethical committee and 
written informed consent was obtained from each patient. Twenty consecutive 
patients with at least one cancer suspicious region (CSR) with a PI-RADS score of ≥3 
detected on the diagnostic multi-parametric MRI, no prior treatment of the prostate, 
and scheduled for MRI-guided biopsy were included. The most recent PI-RADS 
version was used (11,12). The multi-parametric MRI comprised T2-weighted, diffusion- 
weighted, and dynamic contrast-enhanced sequences and was acquired according 
the ESUR guidelines for prostate MRI (11). The size of the CSR was measured on the 
ADC map. The maximal measured diameter was used to classify the CSRs in three 
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different groups: CSRs ≤10 mm, CSRs >10 mm and ≤20 mm and CSRs >20 mm. 
Exclusion criteria were contraindications to MR imaging (e.g. cardiac pacemakers, 
intracranial clips) and biopsy (e.g. rectal pathology).
MR-compatible manipulator
The MR-compatible manipulator used in this study is a second generation remote 
controlled manipulator (RCM) (figure 1) developed by Soteria Medical BV (Arnhem, 
the Netherlands). The device is completely composed of plastic parts and tubing, 
preventing distortion of the magnetic field and enabling optimal patient safety. It is 
very compact, because it was designed to fit between the patient’s legs in the 
restricted space of the MR bore. The RCM is driven by pneumatic air stepper motors 
allowing fast and precise steps for the positioning of the needle guide. In combination 
with a stand-alone computer and dedicated interventional software for planning 
purposes and remote control, the manipulator positions the needle guide relative to 
the suspicious area by using the acquired images. This combination allows for a 
quick interaction to fine-tune the needle guide relative to the gland to adjust for either 
patient motion or tissue obstruction. The stand-alone computer and controller are 
located in the control room next to the MR console. The major differences between 
the new generation and the older version are the specifically designed stepper 
motors and the dedicated software. The new patented motor principle allows for a 
different geometrical setup and therefore a more compact design of the manipulator. 
MRI-guided biopsy procedure
All patients received antibiotic prophylaxis (oral ciprofloxacin, two times a day 500 
mg) during three days, starting on the day before biopsy. The MRI-guided biopsy 
procedures were performed in a 3T MR scanner (MAGNETOM Trio or Skyra, Siemens 
Healthcare, Erlangen, Germany) with the MR-compatible RCM. 
 Patients were positioned in a prone position on the MR table with the RCM 
positioned between their legs. An MR-compatible needle guide (Invivo, Schwerin, 
Germany) was inserted in the rectum and attached to the RCM (Figure 2). A body 
phased-array coil was placed over the patient’s pelvis for signal reception. 
 Axial T2-weighted - and diffusion-weighted images (DWI) were acquired to relocalize 
the cancer suspicious region (CSR) previously detected on the diagnostic multi- 
parametric MRI. Directly after acquisition of the T2-weighted and DWI sequences, 
the images were sent to the standalone PC with dedicated interventional software, 
for optimal positioning of the needle guide for biopsy. The software automatically 
detected the needle guide and highlighted its position with a color overlay on the MR 
images. If necessary, the rotation point of the needle guide could be adjusted manually. 
Subsequently, the radiologist planned and defined the desired target for biopsy. 
The software calculated the optimal path and the RCM steered the needle guide 
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Figure 1 The remote controlled manipulator (Soteria Medical, Arnhem, the Netherlands.
Figure 2  The remote controlled manipulator positioned between the patient’s legs.
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towards this area. The optimal position of the needle guide, the needle track and sample 
core were represented by a blue, yellow and red line overlay (Figure 3). For verification 
purposes of the new position of the needle guide, true fast imaging with steady state 
precession (TrueFISP) images in two directions were acquired.
 If the needle guide position was not aligned correctly with the CSR, for example 
due to resistance of the anal sphincter or patient movement, the position of the 
needle guide was fine tuned with the help of the software followed by new TrueFISP 
images for verification. This step was repeated until the needle guide was correctly 
aligned with the CSR. Eventually, after correct alignment of the needle guide with the 
CSR, a biopsy was taken. The position of the biopsy needle in situ was confirmed 
with TrueFISP images in the sagittal and axial planes (Figure 4). 
 Feasibility and adverse events were reported with rates and description of 
adverse events. Surgical complications were classified according to the modified 
Clavien system for reporting surgical complications.(13) For evaluation of the 
workflow, procedure times were recorded. The total procedure time was defined as 
from the acquisition of the first localizer to the last confirmation image with the biopsy 
needle in situ. Manipulation time was determined as the time required for needle 
guide positioning towards a CSR. The set-up time of the RCM was not measured. 
Figure 3  Screenshot of the planning software accompanying the remote controlled manipulator. 
The current position of the needle guide is represented by the orange line, the desired position 
for biopsy, the needle track and sample core are represented by the blue, yellow and red line 
respectively.
47
FEASIBILITY OF A MR-COMPATIBLE MANIPULATOR FOR PROSTATE BIOPSY GUIDANCE
3
The set-up of the RCM and its PC were quite straightforward; the RCM was positioned 
on the MR-table and its PC was connected to the MR-computer. This was done 
simultaneously with patient positioning on the MR table and did not cost additional 
time. 
Histopathological analyses
The biopsy specimens were subsequently fixed in 10% buffered formalin. Before 
being evaluated by a urogenital pathologist, the samples were embedded in paraffin, 
and stained with hematoxylin-eosin, according to our standard hospital procotol. All 
biopsy samples that were positive for PCa were assigned a Gleason score (GS) 
Figure 4  MR images of a 68 year old patient, PSA 10.1 ng/mL and 3 negative TRUS biopsy 
sessions. A+B: Multi-parametric MRI showed a PI-RADS 5 lesion (yellow circle) in the right 
peripheral zone of the apex of the prostate. C+D : TrueFisp images in two direction acquired 
with the biopsy needle in situ. Histopathologic analyses showed a GS 3+4=7, cancer core 
length 7 mm.
A
C
B
D
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according to the Gleason-scoring system of 2005. Clinically significant PCa was 
defined as GS ≥ 3+4, or GS 3+3 with >1 positive core or a cancer core length >6 
mm(8). 
Results
In total, 20 patients were included in this study. All patient characteristics are shown 
in Table 1. All CSRs were reachable with the RCM and biopsy was performed in all 
patients.
 Two minor complications, classified as Clavien Grade 1, were reported. One man 
experienced extreme nausea and felt the urge to move after sampling the second 
biopsy core. This lead to activation of the safety mechanism, which detached the 
needle guide from the RCM. Two additional biopsy cores were sampled manually. 
Another patient fainted directly after the MRI-guided biopsy procedure. 
Procedure time
The median procedure time was 36:44 minutes with a range of 23 - 61 minutes. 
Median manipulation time for needle guide movement was 5:48 minutes (range, 1:15 
- 18:35 minutes). No additional time was needed to set-up the RCM. 
Table 1  Patient characteristics
Median (range)
Age (y) 68 (51 – 76) 
PSA level (ng/mL) 11.0 (1.5 – 68) 
Previous negative TRUS-guided biopsies (#) 2 (0 – 5)
Prostate volume (cc) 58 (25 – 272)
Time between diagnostic MRI and MRI-guided biopsy (days) 30 (6 – 56)
PI-RADS PI-RADS 3
PI-RADS 4
PI-RADS 5
4
5
12
Biopsy outcomes
No malignancy
Prostatitis
HGPIN
GS 3+3
1
4
1
2
GS 3+4
GS 4+3
GS 4+4
GS 4+5
5
4
1
2
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Histopathologic outcomes
A total of 20 prostate lesions with a PI-RADS score of 3 or higher were detected in 20 
patients (Table 1). A median of 2 biopsies per lesion (range, 2 - 4) were taken. 
Fourteen out of 20 lesions (70%) were proven to be PCa. Twelve out of 20 (60%) were 
clinically significant. Four biopsies contained prostatitis, one contained high-grade 
prostatic intraepithelial neoplasia (HGPIN) and one contained normal prostate tissue. 
Eleven of the lesions were located in the peripheral zone and 9 were located in the 
transition zone. 
Discussion
MRI-guided transrectal prostate biopsy with the aid of an MR-compatible RCM was a 
feasible and safe procedure. All CSRs were reachable with the RCM and the cancer 
detection rate was 70%. The median procedure time was 36:44 minutes (range, 23 - 
61 minutes) and our median manipulation time for needle guide movement was 5:48 
minutes (range, 1:15 - 18:35 minutes). 
 Yakar et al. described the results of the first generation MR compatible manipulator 
and since then no other studies describing this procedure were reported (9). They 
reported a median biopsy procedure time of 76.5 minutes (range, 45-105 minutes), a 
median manipulation time of 2.5 minutes (range, 1-5 minutes) and a cancer detection 
rate of 56%. A systematic review on transrectal MRI-guided prostate biopsies 
published in 2013, found 9 papers describing this procedure in a closed bore system 
(14). In these 9 papers 684 patients were biopsied with a median cancer detection 
rate of 42% (range, 8 - 59%), and the median procedure time for MRI-guided biopsy 
in a closed bore setting was 55 minutes (range, 30 - 68 minutes). 
 Compared to our data, the main improvement is the major decrease in total 
procedure time. With the current RCM, the median procedures times were 
approximately 40 minutes and 20 minutes faster than with respectively the first 
generation manipulator as with the standard manual procedure. The major goal of 
the development of the RCM was to speed up the biopsy procedure and our results 
showed that this is possible. However, our results might have been biased because 
per patient only one CSR was biopsied. Despite the decrease in total procedure time, 
the median manipulation time with the RCM was longer than the median manipulation 
time of the first-generation manipulator. 
 Possible explanations for this are the additional time needed to transfer the data, 
the repeated learning curve for multiple users as well as the built-in safety mechanism 
of the RCM. When the needle guide experienced resistance during movement, the 
RCM stopped moving. This sometimes led to extra iterations of needle guide 
movement, especially for CSRs located in the base or apex of the prostate or CSRs 
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located very laterally. An upgrade of the RCM software enabling adjustment of the 
rotation point of the needle guide is expected to improve this. 
 Next to this, our cancer detection rate was higher than described in the other 
studies. Multiple factors may account for this, as for example the high number of 
PI-RADS 5 lesions (11/20), or it may indicate that performing targeted prostate biopsy 
with our RCM is accurate. However, the real biopsy accuracy should be examined in 
an additional study. 
 Another emerging way to perform targeted prostate biopsies is with MRI-TRUS 
fusion. Previously acquired MR images are fused with real-time TRUS images to 
acquire targeted tissue samples from the suspicious area. Major advantages of this 
technique are that no expensive MR scan time and MR-compatible materials are 
needed when performing a biopsy, however it does require significant investment in 
additional equipment. A recently published review on this subject found a median 
cancer detection rate of 50.5% (range, 23.7 - 82.1) in a total of 2293 patients (15). 
Procedure times were not reported. This was done by Brock et al, who performed two 
targeted fusion guided biopsies in 52 patients and found a mean biopsy procedure 
time of 15 minutes (range, 8-49 minutes), however their detection rate was only 26.4% 
(16). Comparison with manual MRI-guided biopsy is difficult, because in most papers 
more than 1 lesion is targeted and the time per lesion is barely specified. In theory, it 
may turn out that MRI-TRUS fusion biopsy is especially suitable for patients with 
large, high-grade PCa lesions, because these are often better visible on ultrasound. 
In our opinion, in-bore MRI-guided biopsy is more preferable for the smaller lesions. 
However, direct comparison with prospective randomized controlled trials between 
MRI-TRUS fusion biopsy and in-bore MRI-guided biopsy are needed to find out 
which technique is the most appropriate to detect PCa. Recently, the results of a 
randomized study investigating the detection rate of MRI-guided in bore biopsy 
versus the combined approach of MRI-TRUS fusion biopsy with systematic TRUS 
biopsy were published (17). No significant difference was found between both 
groups.
 Our study had a number of limitations. The RCM and its software were 
continuously optimized during this study. However, this is inherent to the natural 
process of a feasibility study. The most significant adjustments were the introduction 
of a direct connection between the MR console and the standalone RCM PC to send 
MR images and the introduction of the software option to adjust the rotation point of 
the needle guide. It is expected that these adjustments will even lead to a further 
decrease of the manipulation and procedure time. Another limitation of this study was 
the relatively small patient population. 
 The next step is to examine the biopsy accuracy of the RCM. For further studies, 
the application of the RCM in combination with an automated real-time needle-guide 
tracking sequence (18), or during MRI-guided transrectal targeted therapies, as for 
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instance focal laser ablation, can be investigated (19). With some minor adjustments 
the RCM may also be used during transperineal prostate biopsies and targeted 
therapies as for example MRI-guided cryoablation (20). 
 In conclusion, It is feasible to perform transrectal MRI-guided prostate biopsy 
using a remote controlled, MR-compatible, manipulator as an aid. It is a fast, and 
therefore efficient way to biopsy suspicious prostate lesions with a minimum number 
of biopsies per patient.
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CHAPTER 4
Abstract
Objective:
The purpose of this article is to evaluate MRI-guided therapies and to investigate their 
feasibility for focal therapy in prostate cancer patients. Relevant articles were retrieved 
using the PubMed online search engine.
Conclusion:
Currently, MRI-guided laser ablation and MRI-guided focused ultrasound are the 
most promising options for focal treatment of the prostate in patients with prostate 
cancer. Other techniques — that is, cryoablation, microwave ablation, and 
radiofrequency ablation — are, for several and different reasons, less suitable for 
MRI-guided focal therapy of the prostate.
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Introduction
Prostate cancer is the most frequently diagnosed cancer, accounting for 28% 
(218,000) of the total number of new cancer cases (1). Prostate cancer is the second 
major cause of cancer death in men, responsible for 11% (32,000) of the total number 
of cancer deaths in men in the United States in 2010 (1). Because of the widespread 
use of the prostate-specific antigen (PSA) test and the lowered PSA threshold for 
biopsy, the number of newly diagnosed prostate cancers has strongly increased (2). 
At present, radical treatment—that is, radical prostatectomy or any form of 
radiotherapy—is not necessary to treat low-grade prostate cancer (Gleason score 
≤ 6). Consensus exists that radical treatment is essential to treat aggressive prostate 
cancer (Gleason score > 6) (3). However, whole-gland treatment can lead to 
significant complications, such as incontinence (20% for radical prostatectomy and 
5% for radiotherapy) and impotence (64% for radical prostatectomy and 66% for 
radiotherapy), and can have a substantial impact on quality of life (4). 
 Consequently, promising techniques such as cryoablation, high-intensity 
focused ultrasound, and laser-induced thermal therapy have emerged as feasible 
minimally invasive focal treatment options. Although most of these techniques are still 
considered experimental for focal treatment of prostate cancer and have not been 
approved by the American Urological Association or European Association of 
Urology and have not been incorporated in national guidelines, most have been 
approved by the U.S. Food and Drug Administration, European Medicines Agency, or 
both. Over the past decade these techniques have been applied more and more in 
the treatment of prostate cancer (5-7). Imaging guidance is imperative in all these 
types of treatment and is provided by transrectal ultrasound (3D), CT, or MRI. Of 
these imaging modalities, MRI — especially multi-parametric MRI — is the most 
sensitive and specific imaging technique for prostate cancer (8). 
 Focal therapy of prostate cancer has the potential to reduce treatment-related 
complications such as incontinence and impotence without making concessions to 
cancer-specific outcome (9). According to Meiers et al. (10), 13–33% of patients with 
prostate cancer have a unifocal prostate cancer lesion and would be eligible for focal 
therapy. Consistent with the “index lesion theory,” even more patients would be 
suitable (11).
 In 2010, a consensus panel of urologic surgeons, radiation oncologists, 
radiologists, and histopathologists from Europe and North America defined focal 
therapy of the prostate as follows (12): “A type of treatment that aims to eradicate 
known cancer within the prostate and at the same time preserve uninvolved prostatic 
tissue with the aim of preserving genitourinary function”. Despite this definition, 
different varieties of focal therapy are described in the literature: hemiablation (i.e., 
treatment of the tumor affected lateralized hemisphere of the prostate), hockey-stick 
58
CHAPTER 4
ablation (i.e., hemiablation of the prostate plus one half of the contralateral hemisphere), 
and targeted focal therapy (i.e., only the tumor itself is treated). 
 On one hand, ample discussion exists about how to select the appropriate 
patient for focal therapy. However, on the other hand, there is almost no discussion 
about the optimal focal therapy method. The latter must meet numerous requirements: 
first, to be able to treat a specific area or one lobe of the prostate; second, to accurately 
shape the ablation zone with no significant effect on the surrounding tissue; third, to 
be minimally invasive with a low pre- and postoperative complication rate; and, fourth, 
to be reproducible. 
 Consequently, the purpose of this article is to evaluate MRI-guided therapies and 
to investigate their feasibility for focal therapy in prostate cancer patients.
Materials and Methods
A systematic literature search was performed. Relevant articles published before 
January 1, 2012, in English, German, or Dutch were retrieved using combinations of both 
medical subject headings and free search terms in the PubMed online search engine 
(U.S. National Library of Medicine). A combination of the following search terms 
was used: MRI, MRI-guided, prostate, ablation, radiofrequency, laser, cryoablation, 
microwave, brachytherapy, (high-intensity) focused ultrasound, focal, and therapy. 
The references of retrieved relevant articles were checked for additional valuable 
articles. Ex vivo, in vitro, and phantom studies were excluded, as well as all studies 
published before 2000 because equipment and techniques have changed 
tremendously since that time. 
 All studies were scored: In each study, data about the study population, sample 
size, ablation technique, adverse events, and MRI methods were documented. 
Results
Cryoablation
In cryoablation, tumor tissue is ablated by freezing. Cryoablation was acknowledged 
as an established treatment option for men with newly diagnosed or recurrent 
organ-confined prostate cancer by the American Urological Association in 2008 (13). 
Cryoablation is usually performed under transrectal ultrasound guidance with a 
transperineal approach; however, cryoablation can also be performed under CT or 
MRI guidance (14,15). 
 In prostate cryoablation, the patient is placed in the lithotomy position. A template 
for needle positioning is placed against the perineum. The 17-gauge cryoneedles 
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are, under imaging guidance, transperineally inserted into the prostate. Because of 
the Joule-Thompson effect, the argon gas within the needle cools to –186°C and 
causes the formation of ice at the tip of the probe and congelation of the surrounding 
tissue. The thawing process can be active (with helium gas) or passive (16). Correct 
needle positioning is essential to freeze as much of the tumor as possible and to 
avoid damaging the surrounding tissues to prevent complications. 
 To date, only limited data about MRI-guided cryoablation study of the prostate 
are available (Table 1). The first results were reported after two canine studies, which 
were performed using an open 0.5T MRI system (17,18): The two groups of 
investigators concluded that MRI-guided cryoablation is technically feasible. 
However, van den Bosch et al. (18) concluded that the volume of the ice ball formation 
during cryoablation of healthy canine prostates as imaged with T1 sequences did not 
match the volume of tissue necrosis induced by the low temperatures. They found 
that contrast-enhanced MRI is a more consistent method for the prediction of tissue 
damage after cryoablation, with an accuracy rate of 91% (Pearson r2 = 0.97). 
Currently, the results of two patient studies have been reported: a study by Reisiger 
et al. (19) and a study by Tsoumakidou et al. (presented at the 2011 annual meeting 
of Cardiovascular and Interventional Radiological Society of Europe). Reisiger et al. 
treated 12 patients with prostate cancer recurrence after radical cryoablation, in a 
1.5T wide-bore scanner. No direct complications were seen. However, within 
3 months of cryoablation, local recurrence abutting the urethra was found in two 
patients. Another patient reported urine retention. Tsoumakidou et al. performed 
MRI-guided prostate cryoablation in a wide-bore 1.5T scanner in seven patients with 
newly diagnosed prostate cancer and in two patients with local recurrence. Besides 
some minor complications such as hematuria, dysuria, and urine retention, one major 
complication was reported: a rectal fistula that spontaneously healed 3 months after 
cryoablation. An advantage of performing cryoablation under MRI guidance instead 
Table 1  Literature overview on MRI-guided cryoablation of the prostate
Author Year Study 
type
N MR field strength 
and configuration
Treatment 
method
Reisiger et al. (19) 2011 Patient 12 1.5T, wide bore Transperineal
Tsoumakidou et al. * 2011 Patient 9 1.5T, wide bore Transperineal
Josan et al. (17) 2009 Canine 13 0.5T, open bore Percutaneous
Van den Bosch et al. (18) 2009 Canine 6 0.5T, open bore Percutaneous
*presented at the 2011 meeting of the Cardiovascular and Interventional Radiological Society of Europe.
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of transrectal ultrasound guidance is the possibility to insert a rectal balloon with 
warm water to protect the rectal wall from freezing. 
 All the aforementioned advantages of MRI guidance, compared with other 
imaging modalities, do count for cryoablation except the possibility of temperature 
mapping. Temperature mapping is unfortunately not possible for temperatures below 
0°C with the currently available clinical MR temperature sequences. Although the 
temperature gradient within the ice ball is not measurable with MR temperature 
mapping, ice ball formation is visible on real-time MRI. Nevertheless, investigators 
have reported that the volume of the ice ball does not match the volume of tissue 
necrosis (18). As a consequence, attention should be paid to the size and location of 
the lesion that needs to be ablated and a safety margin of a few millimeters should be 
applied. Another disadvantage is that the cryoneedles cause an image artifact that is 
more pronounced on a T1-weighted sequence than on a T2-weighted sequence.
Focal laser ablation treatment
Focal laser ablation, sometimes also referred to as laser-induced thermal therapy, is 
a relatively new technique that was originally developed to treat brain tumors (20). 
During this therapy, a laser fiber is positioned in the tumor under imaging guidance 
(ultrasound or MRI). When the position of the fiber is correct, a laser light with a 
wavelength of 980 nm is delivered through the fiber and the temperature of the tissue 
around the tip of the fiber increases. When the temperature of the tissue reaches 
more than 60°C, the tissue is irreversibly damaged and destroyed. The total ablation 
process takes up to 3 minutes. The laser fiber is placed inside a cooling catheter 
throughout the ablation to prevent carbonization of the adjacent tissue and to increase 
laser light penetration depth. 
 Studies reporting on MRI-guided prostate focal laser ablation are scarce 
because it is a considerably new technique (Table 2). Stafford et al. (21) and Peters 
et al. (22) were the first to report on MRI-guided focal laser ablation in prostates, 
although both groups reported the results of animal studies. The most important 
conclusion was that the damage predicted with MR temperature mapping correlated 
with the damage seen on 3D T1-weighted contrast-enhanced images, with a slope 
near unity and excellent correlation (r2 = 0.94) (21). Complication rates were not 
reported because the animals were sacrificed immediately after the procedure. 
 Raz et al. (23) treated two patients with MRI-guided transperineal focal laser 
ablation at 1.5T. Real-time MRI guidance was used during targeting of the tumor with 
the laser fiber and to control tissue temperature during the ablation. Patients were 
discharged 3 hours after treatment. No adverse events were found in the 1 month of 
follow-up. Woodrum et al. described MRI-guided focal laser ablation at 3T field 
strength; however, their study was a feasibility study performed using cadaveric 
prostates (24). The same group also treated a patient with local recurrence of prostate 
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cancer after a radical prostatectomy at 3T field strength (25). Early follow-up showed 
no posttreatment incontinence, rectal wall injury, or other complications . In both 
studies, investigators concluded that MRI-guided focal laser ablation on a 3T system 
is uniquely suited and is a promising technique for accurate focal targeting of prostate 
cancer because of the inherent high spatial and temporal resolution of MRI (24,25). 
 One of the key features of focal laser ablation is that the fibers used during laser 
ablation cause no distortion of the electromagnetic field, so no image artifacts exist 
in the region of interest (26). In addition, the treatment time is quite short and the 
ablation zone is sharply defined compared with other ablation techniques (21,27).
Focused Ultrasound
Compared with the aforementioned techniques, focused ultrasound is the only real 
noninvasive ablation technique. A transducer directs a high-intensity ultrasound 
beam to converge and focus at a certain point in the tissue with this technique. The 
energy of the ultrasound waves is sufficient to heat up the tissue and to surpass the 
thermal dose threshold obligatory for coagulative necrosis in a few seconds. When 
the transducer consists of multiple piezoelectric elements, greater flexibility in 
targeting and shaping of the focal spot can be reached (28). 
 For prostate cancer, the transducer can be applied in various ways: transrectal 
(29,30), which is the most applied method; transurethral (31,32); extracorporeal, with 
the transducer placed against the perineum (33); and interstitial (34), with the 
transducer inserted transperineally, which is no longer noninvasive. 
 Experience in MRI-guided focused ultrasound has been gained in the treatment 
of uterine fibroids (35,36). Gradually the treatment area is now being extended to 
other organs and tissues such as breast, liver, and bone (37-39). 
Table 2  Literature overview on MRI-guided FLA of the prostate
Authors Year Study 
type
N MR field strength 
and configuration
Treatment 
method
Woodrum et al. (25) 2011 Patient 1 3.0T Transperineal
Raz et al. (23) 2010 Patient 2 1.5T Transperineal
Woodrum et al. (24) 2010 Human 
cadaver
5 3.0T Transperineal
Stafford et al. (21) 2010 Canine 7 1.5T Laparotomya 
Transperinealb 
Peters et al. (22) 2000 Canine 2 1.5T Percutaneous
aTwo dogs; bFive dogs
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To date, only a few studies have been published about MRI-guided focused 
ultrasound of the prostate; however, most were performed using dogs (Table 3). 
McDannold et al. (30) performed the only study of focused ultrasound treatment 
under 3T MRI guidance on four dogs using a transrectal probe. They concluded that 
MRI-guided focused ultrasound is feasible in the prostate. However, prostate 
movement was an important issue. Other results described in these animal studies 
were the small transition zones of 0.4–2.0 mm present between ablated tissue and 
viable tissue (30,32,40).
Siddiqui et al. (32) treated five patients with clinically proven prostate cancer (PSA < 
15 ng/mL, T1c or T2a, and Gleason score ≤ 7 [3 + 4]) using transurethral MRI-guided 
focused ultrasound immediately before radical prostatectomy. Approximately 30% of 
the prostate volume was ablated to examine the technical feasibility of the technique. 
The treatment was well tolerated by patients and no complications were seen during 
or after surgery. Overlapping results of the same research group were reported by 
Chopra et al. (40).
 A substantial limitation of MRI-guided focused ultrasound is the extensive 
ablation time (≈ 2–2.5 hours, with incidental peaks to > 6 hours (41)), which makes 
this technique more suitable for focal therapy than for whole-gland therapy. Another 
disadvantage is that the focal spot loses its correct position in relation to the tumor if 
the patient moves or if there is any movement of the tumor within the body during 
treatment. 
Table 3  Literature overview on MRgFUS of the prostate
Author Year Study type N MR field strength 
and configuration
Treatment 
method
Siddiqui et al. (32) 2010 Patient 5 1.5T Transurethral
Chopra et al. (40) 2010 Patient 8 1.5T Transurethral
Siddiqui et al. (32) 2010 Canine 17 1.5T Transurethral
Chopra et al. (40) 2010 Canine 25 1.5T Transurethral
McDannold et al. 
(30)
2009 Canine 4 3T Transrectal
Chen et al. (31) 2008 Canine 6 0.5T, open bore Transurethrala
 Interstitialb
Nau et al. (34) 2005 Canine 2 0.5T, open bore Interstitial
aFour dogs; bTwo dogs
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Besides thermal ablation, focused ultrasound has another promising clinical 
application: targeted drug delivery. The drug—for example, a chemotherapeutic 
agent—can be encapsulated and can be systematically administered to the body. 
The release of the drug can be locally activated by heat from or mechanical oscillation 
of the focused ultrasound waves (42).
Radiofrequency Ablation
During radiofrequency ablation (RFA), a needle electrode needs to be inserted into 
the tumor tissue. This electrode produces electromagnetic waves with a maximal 
frequency of 30 MHz. The waves cause friction within the tissue that raises the 
temperature and causes cell death (43). 
 Terraz et al. (44) performed MRI-guided RFA of 16 small liver malignancies in 
10 patients. All patients were treated successfully, and Terraz et al. concluded that 
MRI-guided RFA was technically feasible. They did not notice any influence of the 
radiofrequency signals (470 kHz) on the signal-to-noise ratio (SNR). To our knowledge, 
there are no reports about MRI-guided RFA for (focal) treatment of prostate cancer. 
 Obviously, clinical experience performing MRI-guided RFA of the prostate is still 
very limited, probably because of technical difficulties. The major drawbacks of 
MRI-guided RFA are possible interference with the radiofrequency pulses of the MR 
system and the large image artifact (up to eight times its original size) caused by the 
radiofrequency electrode. The latter makes temperature measurement at the vicinity 
of the electrode impossible (45).
Microwave Ablation
Microwave ablation is almost identical to RFA. Again, an applicator—in this setting, an 
“antenna”—is inserted into the lesion that needs to be ablated. Then, electromagnetic 
waves, with a frequency between 30 MHz and 30 GHz, are sent through the antenna 
and cause heating and finally destruction of the tissue (46). A drawback of this 
technique is that the electromagnetic waves can interfere with the radiofrequency 
signals used for MRI, which can cause noise in the MR images.
 Chen et al. (47) described in 2000 their first clinical results with microwave 
ablation using a frequency of 915 MHz under 1.5T MRI guidance in five patients with 
local recurrence of prostate cancer. The microwave applicators were transperineally 
inserted under transrectal ultrasound guidance, and patients were then transferred to 
the MR room for MRI-guided microwave ablation. All patients were treated 
successfully, but 6 months after ablation, the PSA levels of two patients started rising 
again. The microwave applicators caused only little artifact on the MR images. 
However, when the microwave power was turned on, a large increase of noise was 
seen. Consequently, the SNR and accuracy of MRI thermometry were influenced in 
a negative way.
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Brachytherapy
Brachytherapy is a type of radiotherapy in which the radiation source is placed near 
or inside the treatment area. For the treatment of prostate cancer, brachytherapy can 
be used as permanent low-dose-rate (LDR) seed implantation or as temporary 
high-dose-rate (HDR) brachytherapy (48).
 During LDR brachytherapy a large number of 125I seeds are implanted in the 
prostate via transperineally inserted catheters. MRI-guided LDR brachytherapy has 
been performed by D’Amico et al. (49) and Van Gellekom et al. (50) (Table 4). The first 
group treated 43 patients in a 0.5T openbore MRI scanner. Several catheters were 
inserted under MRI guidance, and a median of 80 125I seeds (range, 43–120 seeds) 
were left in the prostate. One month after treatment, no sexual or gastrointestinal 
dysfunction was reported (49). Van Gellekom et al. treated five patients in a 
conventional 1.5T closedbore scanner with a single-needle method. Only one needle 
was inserted through the perineum; it was repeatedly inserted at different angles in 
the prostate to implant the iodine seeds (50). 
HDR brachytherapy of the prostate uses an 192Ir source that is temporarily placed 
inside the treatment-requiring area via hollow closed-tip catheters that are inserted 
through the perineum (48). Different groups have performed this therapy under MRI 
guidance (51-53). Ares et al. (51) used HDR brachytherapy as an extra boost for only 
a partial volume of the prostate after external beam radiation therapy (EBRT) in 77 
patients. In seven patients, only one lobe of the prostate was treated. Ares et al. 
reported that the long term toxicity has been limited and that biochemically 
disease-free survival rates were encouraging. In all three studies, cancer localization 
and catheter insertion were performed under MRI guidance; thereafter, the patient 
Table 4  Literature overview on MRI-guided Brachytherapy of the prostate
Author Year Study 
type
N MR field strength 
and configuration
Treatment 
method
Permanent low-dose-rate seed implantation
Van Gellekom et al.(50) 2004 Patient 5 1.5T Transperineala
D’Amico et al. (49) 2000 Patient 43 0.5T, open bore Transperineal
Temporary high-dose-rate brachytherapy
Ares et al. (51) 2009 Patient 77 0.23T, open bore Transperineal
Menard et al. (52) 2004 Patient 5 1.5T Transperineal
Susil et al. (53) 2004 Patient 4 1.5T Transperineal
aSingle needle
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was moved to a shielded room for radiation delivery (51-53). The overall procedure 
time was between 4.5 and 9.5 hours (52,53). 
 A key characteristic of brachytherapy is that the irradiation harms only a very 
small area around the radiation source and exposure of healthy tissues farther away 
from the sources is therefore reduced. Major drawbacks of brachytherapy are the 
long procedure time and use of radioactive materials. For this latter reason, extra 
precautionary measures need to be taken (e.g., rooms with extra shielding) when 
performing HDR brachytherapy.
Discussion
In modern medicine the drive is toward the development and improvement of 
treatments and techniques that minimize intervention to the patient and hospitaliza-
tion. MRI-guided interventions provide a minimally invasive approach to cancer 
therapy that is gaining clinical acceptance. Of the available techniques, we consider 
MRI-guided focal laser ablation to be the most sophisticated focal therapy treatment 
option in the prostate. It appears to be fast and feasible because of the sharply 
defined ablation zone, no distortion of laser fibers, few anticipated low adverse events 
and complications, quick recovery of patients, and possibility to repeat the therapy 
as often as needed. Furthermore, it is easy to fit in clinical practice. 
 MRI-guided focused ultrasound alone or combined with local drug delivery is a 
promising technique for focal therapy in the prostate. It has the potential to surpass 
focal laser ablation as the most sophisticated technique because it is not invasive 
and is highly accurate given the small focal spot. However, to achieve this, the relative 
long treatment time even for small lesions needs to be shortened and the first 
experiments of patients need to be performed. 
 HDR brachytherapy can be performed under MRI guidance to give a local boost 
to the tumor as a supplement to EBRT of the entire prostate. For both types of 
brachytherapy, MR images can be used to localize the tumor and to monitor the 
insertion of the catheter and seeds in real time. During the actual therapy, MRI has no 
surplus value because this cannot be seen on the MR images. 
 The other techniques—cryoablation, microwave ablation, and RFA—are, for 
several and different reasons, less suitable to use for MRI-guided focal therapy of the 
prostate. According to the first results in patients and animals (17,18,30) and earlier 
results under ultrasound guidance (6,54-58), MRI-guided cryoablation of the prostate 
is feasible even for focal therapy. However, because of the indistinct ablation zone, 
a safety margin of a few millimeters should be applied. Furthermore, MRI-guided focal 
cryoablation can be repeated, is minimally invasive, and has a relative low complication 
rate. 
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Microwave ablation and RFA work with electromagnetic waves that can possibly 
interfere with the radiofrequency signals of the MR system itself (45). These signals 
are dependent of the field strength of the magnet, in the range of 0–128 MHz when 
using a 1.5- or 3T magnet. This possible interference makes these treatments less 
suitable for focal therapy because the tissue temperature of the adjacent healthy 
structures needs to be monitored carefully. 
 In general, the benefits of performing an intervention under MRI guidance (i.e., 
the accuracy during needle placement or the possibility of temperature mapping 
during the procedure) should be considered carefully against the disadvantages. 
These disadvantages include increased costs, difficult patient selection considering 
the multifocality of prostate cancer (this also accounts for transrectal ultrasound–
guided procedures), limited amount of space during the procedure for the patient 
and physician, the need for special MR-compatible materials, and the limited time 
available in MRI scanners. Nevertheless, MR systems are increasingly being adjusted 
to allow interventional MRI. New systems with shorter and wider bores are being 
produced to provide more space for the patient and the physician as well. 
 Another way to overcome the accessibility problem and to speed up the 
procedure is to perform part of the procedure with the help of an MRI-compatible 
robot. Several robots for needle placement and LDR seed implantation have been 
described in the literature and the results of these studies are promising (59-62). 
 To date, the issue of how to select the appropriate patient for focal therapy has 
been discussed extensively. Several methods are used for prostate cancer diagnosis 
and staging: digital rectal examination, PSA test, and transrectal ultrasound–guided 
prostate biopsy. Nevertheless, these techniques are not accurate enough and fail to 
reveal a large fraction of clinically significant tumors (63). Transrectal ultrasound–
guided transperineal mapping or saturation biopsies were introduced to avoid missing 
clinically significant tumors. However, these biopsies have major disadvantages such 
as the need for anesthetics, patient discomfort, and intensive pathologic processing 
(64,65). Currently, multi-parametric MRI is the most sensitive and specific imaging 
technique for prostate cancer (8) and should certainly be used for proper patient 
selection for focal therapy. 
 The largest limitation of this review is the sparse amount of data. Unfortunately 
data published on this subject are limited and most of the studies have a small study 
group and a short follow-up. 
 Future steps will be to validate these new procedures in prospective clinical trials 
with more patients and longer follow-up periods and to compare them with active 
surveillance and radical therapies in randomized controlled trials.
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Conclusion
MRI-guided focal therapy of the prostate seems possible with the present techniques; 
however, the one method is more feasible than another.
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Abstract
Purpose:
To correlate T1-weighted (T1w) magnetic resonance (MR) image contrast around a 
cryoablation iceball with temperature in a phantom study and to compare this to its in 
vivo appearance during MRI-guided focal cryoablation of prostate cancer. 
Methods:
A MR-compatible cryoneedle was inserted into identical gel phantoms (n = 3) on a 
1.5 T MR system. Two fiber-optic temperature sensors were placed parallel to the 
needle. A fast 3D T1w gradient echo (GRE) sequence (TR/TE/FA= 4.81/1.98/6⁰) was 
used to monitor iceball progression. Normalized signal intensity (SI) was correlated 
with temperature. The same T1w sequence was used during MRI-guided prostate 
cryoablation in ten consecutive patients at the authors’ institution. In vivo findings 
were quantitatively compared to the phantom data.
Results: 
In the phantom study, the cryoablation iceball appeared in the T1w MR images as a 
sharply delineated signal void. A 2.2±0.2 mm wide hyperintense rim directly 
surrounded the iceball at cooled but nonfreezing temperatures (<20 ⁰C) in the gel. 
Normalized SI was maximum at 8.4±2.4 ⁰C, showing a 35.6%–43.0% (mean 40.5%) 
increase with respect to baseline before cooling. In the clinical procedures, the same 
image contrast was observed in vivo in all patients. In vivo, width of the hyperintense 
rim was 1.6±0.6 mm. Normalized SI increases with respect to nontreated prostate 
ranged 28.4%–55.6% (mean 36.8%). On quantitative analysis, normalized SI changes 
along a linear region of interest from surrounding tissue onto the iceball center were 
similar between the patients and phantom setting (root mean square difference 0.06).
Conclusions: The hyperintense rim around the iceball in fast T1w GRE images 
corresponded to cooled but nonfreezing temperatures (<20 ⁰C) proximal to the 
frozen zone. The same image contrast was observed both in a phantom study as well 
as in vivo in the human prostate during cryoablation. Potentially, monitoring of this rim 
could be useful in order to maintain a safety margin from at-risk tissues during 
MRI-guided prostate cryoablation procedures. 
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Introduction
Magnetic resonance imaging (MRI) -guided cryoablation is an upcoming and 
promising minimally invasive treatment for localized prostate cancer (PCa)(1-3). One 
of the main challenges in prostate cryoablation is to achieve radical cancer ablation 
without inducing freeze injury to nearby vital structures (4). As up to 70%–80% of 
prostate cancers is located in the peripheral zone (5), particularly the rectal wall and 
neurovascular bundles are at risk. In order to avoid complications, subzero 
temperatures should be avoided in the vicinity of these structures.
 Currently, temperature monitoring in tissues surrounding the ablation zone is 
performed using invasive thermocouple probes (6-8). This approach may be time 
consuming, poses risks of puncture complications, and only yields temperature 
measurements at discrete locations. A noninvasive imaging-based method would 
therefore be desirable.
 MRI-guidance of cryoablation enables monitoring of the ablation zone in 3D with 
excellent depiction of the ice–tissue boundary (9,10). However, an important limitation 
of conventional imaging sequences is the inability to visualize the thermal gradient 
in tissues surrounding the iceball. Previously, several studies on the MR monitoring 
of cryoablation have noted a thin rim of increased signal around the iceball in 
fast T1-weighted (T1w) gradient echo (GRE) images, presumably representing the 
temperature gradient in adjacent cooled but nonfrozen tissue (11-13). Potentially, 
this image contrast could allow insight into the temperatures induced proximal to the 
ablation zone during MRI-guided cryoablation procedures. However, to our knowledge, 
this signal deviation has never been experimentally investigated nor explored in vivo 
in patients.
 This study aims to correlate T1w MR image contrast around a cryoablation iceball 
with temperature in a phantom study and to compare this to its in vivo appearance 
during MRI-guided focal cryoablation of PCa.
Materials and methods
Theory
The effects of temperature on MR signal have previously been explored for several 
applications, including the monitoring of thermotherapy. Gultekin et al. reported a 
comprehensive overview of the temperature dependency of several MR properties 
and their combined effects on the magnitude of the MR signal (14). First, MR signal is 
proportional to the nuclear magnetization (M0), which has a negative temperature 
dependency (i.e., M0 will increase when absolute temperature drops). Second, MR 
signal is dependent on the relaxation times (T1, T2), which may differ at different 
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temperatures, for different substances measured, and depend on magnetic field 
strength (15). In the temperature range above the freezing point, T1 exhibits a rather 
strong temperature dependency, showing a linear increase with temperature of 
approximately 1.0%–2.0% per ⁰C (16-19). In addition, temperature dependency of T1 
increases with field strength (20). T2 on the other hand appears to be relatively 
temperature insensitive in the same temperature range (17,18,21,22). Finally, 
experimental parameters such as echo time (TE) and repetition time (TR) determine 
the sensitivity of a MR sequence for the temperature dependent relaxation effects. 
 In this study, a gel phantom and in vivo prostate tissue are imaged during 
cryoablation using a fast T1w GRE sequence at 1.5 T. Above the freezing point, we 
anticipate that as tissue cools, equilibrium magnetization (M0) will increase as given 
from the Boltzmann distribution (14). In addition, due to its linear temperature 
dependence, T1 is expected to shorten with decreasing temperature. Down to 0 ⁰C, 
this has also been experimentally demonstrated by Fung et al (20). 
 As a result of these effects, in a GRE sequence a decrease in temperature (T) 
would give rise to an increase in received MR signal (S), with its magnitude modulated 
by the measurement parameters TE, TR, and flip angle θ (14). Therefore, in a T1w 
GRE sequence, cooled tissue would be expected to exhibit increased signal as 
compared to uncooled tissue. Due to the exponential terms in Eq. (1), this signal 
increase may be nonlinear. For freezing temperatures, MR signal is expected to be 
rapidly lost owing to extreme T2 shortening as free water is taken up into ice crystals 
(23,24).
(Eq. 1)
Phantom study
Three identical gel phantoms (23×14×6 cm) were prepared consisting of demineralized 
water and 3% carrageenan as a gelling agent. Following the method proposed by 
Kato et al., different concentrations of GdCl3 as T1 modifier and agarose as T2 
modifier were added to obtain MR relaxation properties equivalent to prostate tissue 
at 1.5 T (T1=1317 ms; T2= 88 ms) (25) as well as NaCl to obtain tissue equivalent 
dielectric properties (26,27). Prior to the experiments, phantoms were kept overnight 
in a stove set at 37 ⁰C in order to bring the gel to body temperature. 
 Each phantom was positioned in a 1.5 T MRI system (Magnetom Avanto, 
Siemens, Erlangen, Germany) with a body phased-array coil placed over the phantom 
for imaging. Using a perspex frame, a MR-compatible cryoneedle (IceRod, Galil 
Medical, Yokneam, Israel) was inserted into the phantom. Using plastic coaxial 
needles (Invivo, Schwerin, Germany), two fiber-optic temperature sensors (Neoptix, 
Quebec, Canada) were inserted parallel to the cryoneedle at a lateral distance of 0.5 
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and 1.0 cm (Figure 1A). A third temperature sensor was placed on the contralateral 
side of the phantom for reference. Temperature readings throughout the experiment 
were recorded at 1 s intervals. Baseline T1 measurement was performed using four 
consecutive multislice spoiled GRE sequences with varying flip angles (TR = 3.85 
ms, TE = 1.42 ms, FA= 2⁰/5⁰/10⁰/20⁰, slice thickness = 3.6 mm, FOV= 260 mm, 
matrix size 160×160, averages = 6, and TA = 43 s). Using the MRI SeedNet system 
(Galil Medical, Yokneam, Israel), freezing was applied until the iceball was maximal in 
size. Continuous MR monitoring of iceball progression was performed using a 
coronal 3D T1w volume interpolated GRE sequence (TR = 4.81 ms, TE = 1.96 ms, 
FA= 6⁰, partition thickness = 2.5 mm, FOV= 250 mm, matrix size 192×192, averages 
= 1, phase oversampling = 0%, slice partial Fourier = 6/8, PAT mode = GRAPPA, 
acc. Factor PE = 2, no. of partitions = 26, pixel bandwidth = 389 Hz/pixel, and TA = 
11 s). At the end of the experiment, T1 measurement was repeated.
 After the experiments, MR images and temperature readings were analyzed 
using Matlab R2011a (Mathworks, Natick). In order to obtain signal intensity (SI) 
values representative for the sensor locations, its positions were mirrored across the 
center line of the cryoneedle (Figure 1B). For the mirror positions, SI over the 
experiment was extracted, normalized to its baseline value before cooling, and 
related to measured temperatures. 
 For quantitative analysis, in the last image of each experiment, a linear region of 
interest (ROI) extending from 1 cm into the surrounding gel onto the center of the 
iceball was selected. SI along this line was normalized to its first three values and 
plotted against position. Full width at half maximum (FWHM) was used to determine 
the width of the hyperintense rim surrounding the iceball.
Figure 1  A: Setup for the phantom study showing the cryoneedle and temperature sensor 
positions at lateral distances of 0.5 (I) and 1.0 cm (II). B-E: Fast T1w GRE images at different 
time points during one of the phantom experiments with sensor locations (+) and mirrored 
positions (*) overlaid and corresponding temperature recordings indicated. (F) Calculated T1 
map (s) at the end of ablation reveals shortening of T1 directly adjacent to the iceball. Some 
distortion in the T1 map can be seen below the iceball arising from the artifact of the cryoprobe 
shaft.
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Finally, T1 maps at baseline and end of ablation were generated using the variable flip 
angle (VFA) method (28). For each experiment, mean T1 value at baseline was 
determined for a 5×5 voxel ROI selected centrally in the phantom. Similarly, mean T1 
value around the iceball at the end of ablation was determined for 10 voxels directly 
adjacent to the frozen area.
Clinical procedures
The same T1w sequence was used during MRI-guided focal cryoablation in ten 
patients at our institution with biopsy-proven local recurrence after radiotherapy (n = 9) 
or newly diagnosed prostate cancer (n = 1) located in the peripheral zone (n = 9) or 
transition zone (n = 1). In all patients, informed consent was obtained. Procedures 
were performed on the same 1.5 T MRI system and used the same imaging setup as 
in the phantom experiment. Patients were treated under general anesthesia. After 
insertion of a urethral warming catheter, patients were positioned in the lithotomy 
position. Axial and sagittal T2-weighted turbo spin echo (TSE) imaging was performed 
to relocalize the tumor. Cryoneedles were inserted transperineally into the target 
region under balanced steady state free precession (bSSFP) real-time MR image 
guidance. After confirming correct needle placement, a rectal warming balloon was 
inserted. During freezing, both warmers were flushed with warm (43 ⁰C) saline. Two 
cycles of 10 min freezing and 3 min thawing were applied. Iceball growth was 
continuously monitored in axial orientation using the 3D T1w volume interpolated 
GRE sequence (TR = 4.81 ms, TE = 1.96 ms, FA= 6⁰, partition thickness = 2.5 mm, 
FOV= 250 mm, matrix size 192×192, averages = 2, phase oversampling = 88%, 
slice partial fourier = 6/8, PAT mode = GRAPPA, acc. factor PE = 2, no. of partitions 
= 26, pixel bandwidth = 389 Hz/pixel, and TA = 50 s). Further procedure details have 
been described previously (2). 
 After the procedures, MR images were analyzed quantitatively. In two patients, 
image quality was insufficient for quantitative analysis due to excessive noise. In each 
of the remaining eight patients, a similar linear ROI as in the phantom was selected in 
the last image of the procedure. Care was taken not to select the line ROIs in close 
proximity to the edge of the prostate or near the rectum or urethra. SI along the line 
ROIs was normalized to its first three values and compared to the phantom data by 
calculating the maximum and root mean square difference (RMSD) between the 
curves of both settings. FWHM was used to determine the width of the hyperintense 
rim surrounding the iceball.
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Results
Phantom results
Baseline temperature of the phantom was 39.9 ±1.8 ⁰C. No substantial deviation 
(<1⁰C) from this baseline was observed at the contralateral side of the phantom 
during all experiments. Baseline T1 of the phantom was 1372 ± 89 ms. 
 In the phantom, the iceball appeared in the fast T1w GRE images as a sharply 
delineated signal void, directly surrounded by a bright hyperintense rim. On correlation 
of MR images with the sensor readings, the rim coincided with temperature recordings 
in the gel near but above the freezing point (Figure 1C-E). 
 Also when normalized SI is plotted against temperature, a pronounced signal 
increase can be observed in the cooled but nonfreezing temperature range (<20 ⁰C) 
(Figure 2). When temperature entered the freezing range, normalized SI decayed 
rapidly with no measurable signal remaining at −5 ⁰C. Normalized SI was maximum 
at 8.4 ± 2.4 ⁰C, showing a 35.6%–43.0% (mean 40.5%) increase with respect to 
baseline before cooling. Width of the hyperintense rim was 2.2 ±0.2 mm. T1 directly 
adjacent to the iceball at the end of ablation was 631 ± 72 ms, showing a 54% 
shortening with respect to baseline (Figure 1F).
Figure 2  Normalized SI correlated with measured temperature for both sensor positions (I, II) 
in the three phantom experiments (A, B, C).
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In vivo findings
In all clinical procedures, fast T1w GRE imaging allowed the continuous monitoring of 
iceball progression. In the in vivo MR images, in all patients, the cryoablation iceball 
appeared similarly as in the phantom study, i.e., as a signal void surrounded by a 
hyperintense rim (Figure 3). In vivo, normalized SI increases with respect to nontreated 
prostate ranged 28.4% – 55.6% (mean 36.8%). 
Figure 3  A: Axial T2-weighted TSE image and corresponding B: axial dynamic contrast 
enhanced (DCE) image of diagnostic prostate MR examination in one of our patients prior to 
cryoablation, showing a cancer suspicious region in the right peripheral zone (outline). C: Axial 
T2w TSE image during the procedure shows two cryoneedles (arrows) positioned near the 
target area. D: Axial fast T1w GRE image acquired during cryoablation. The growing iceball (IB) 
is readily visible as a signal void directly surrounded by a bright hyperintense rim (arrowheads).
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On quantitative analysis, normalized SI changes along the linear ROI at the end of 
ablation were similar between the phantom and in vivo data (RMSD 0.06, maximum 
difference 0.16) (Figure 4). In vivo, width of the hyperintense rim around the iceball 
was 1.6 ± 0.6 mm.
Discussion
Similar studies on the MR monitoring of cryoablation have mainly focused on 
measuring temperatures inside the iceball using ultrashort TE (UTE) sequences 
(29-32). In contrast, this work focused on the monitoring of tissue external to and 
surrounding the cryoablation zone. Research exploring the use of novel MR strategies 
to visualize the temperatures induced in tissues around the frozen area is limited. 
Rothgang et al. have investigated the use of proton resonance frequency shift (PRFS) 
thermometry proximal to the cryoablation zone, however, high sensitivity of this 
technique to iceball induced susceptibility artifacts was found to considerably 
influence accuracy of the temperature maps and correction algorithms need further 
Figure 4  A: Normalized SI along the linear ROI at the end of the ablation for the phantom 
experiments and patient group with corresponding standard errors. B and C: Fast T1w GRE 
images at the end of one of the phantom experiments (B) and clinical procedures (C) show the 
ROI selection.
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validation (33,34). Alternatively, this study investigated T1w image contrast around the 
iceball, correlated it with temperature, and explored its in vivo appearance in patients.
 In our phantom study (n = 3), we found the hyperintense rim around the iceball 
in fast T1w GRE images to correspond to cooled but nonfreezing temperatures 
(<20 ⁰C) proximal to the frozen zone. The signal increase at low temperatures can be 
mainly attributed to T1 shortening. Normalized SI was maximum at 8.4 ± 2.4 ⁰C. 
Theoretically, normalized SI would be expected to reach a maximum around 0 ⁰C, 
directly before the freezing-related signal loss (35). This was also found experimentally 
by two studies that have used UTE imaging to investigate the temperature dependency 
of MR signal in the cryogenic range (29,30). The incongruence with our findings is 
probably due to the use of a short TE (~2 ms) in our study compared to ultrashort 
TEs (~200 μs) applied in the latter experiments. At the ice–tissue transition, the 
susceptibility difference between the frozen and unfrozen tissue states may result in 
a local T2* decrease. Although 2 ms was the shortest TE that could be set on the 
clinical MR system used in this study, this could have reduced the signal measured 
with our imaging sequence close to the iceball boundary.
 In vivo, normalized SI increases were in a comparable range with those in the 
phantom study, with the mean value appearing slightly lower in the patient setting 
(40.5% vs. 36.8%). A noted difference between findings in both settings was the 
smaller width of the hyperintense rim in vivo than in the phantom (~1.6 vs. 2.2 mm). 
This suggests that in the in vivo prostate, the cooled nonfreezing temperatures 
induced around the iceball are restricted to a smaller area as compared to the 
phantom, indicating the presence of a steeper spatial temperature gradient. Tissue 
perfusion, acting as a cold sink, or cellular boundaries affecting the extension of ice 
crystal formation could explain this observation.
 The contrast observed around the cryoablation iceball in fast T1w GRE imaging 
may hold potential for clinical use. The visualization of cooled nonfreezing temperatures 
allows insight into the temperature distribution in the surrounding tissues. Particularly 
since there may be a considerable time gap between MR image acquisition, 
subsequent assessment of ice progression and cryoprobe modulation, this could be 
an important capability. In addition, several studies on nonfreezing cold injury have 
demonstrated free radical formation to occur at temperatures near but above the 
freezing point (36,37). Potentially, monitoring of the hyperintense rim may then be 
useful in order to maintain a safety margin from at-risk structures. Nevertheless, our 
in vivo study was only explorative and a potential clinical use of our findings will need 
to be validated by including procedure-related complications and follow-up imaging 
or histopathology following cryoablation. 
 Some limitations of this study need to be acknowledged. In several animal 
studies on cryoablation, temperature measurements have been obtained in vivo by 
means of thermocouples or fiber-optic probes (29,32,38). In our patient group, no 
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reference temperature measurements could be obtained in vivo. To the best of our 
knowledge, no MR-compatible temperature probes that are approved for in-patient 
use were commercially available at the time this study was conducted. To be able to 
compare results between the phantom and patient setting, care was taken to prepare 
the gel phantom with tissue-equivalent MR relaxation and thermal properties and to 
use the same imaging parameters in the phantom study as in vivo.
 In the phantom study, we chose to mirror the sensor positions across the 
cryoneedle in order to obtain representative SI values. In other studies, ROIs were 
chosen directly adjacent to or in an area around and including the temperature 
probes (11,29). Due to the thermal gradient present in the tissue, any position offset 
may result in considerable error matching measured temperatures to SI. By mirroring 
the sensor positions, we tried to minimize any error in the correlation between 
normalized SI and temperature, assuming symmetric growth of the iceball in the 
homogeneous gel phantom.
 In conclusion, this study has shown the hyperintense rim surrounding the iceball 
in fast T1w GRE images to correspond to cooled but nonfreezing temperatures 
(<20⁰C) induced proximal to the frozen zone. We observed the same image contrast 
both in a phantom study as well as in vivo in the human prostate during cryoablation. 
Potentially, monitoring of this rim could be useful in order to maintain a safety margin 
from adjacent at-risk tissues during MRI-guided prostate cryoablation procedures.
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CHAPTER 6
Abstract
Purpose:
To assess the feasibility of magnetic resonance imaging (MRI)–guided focal cryoablation 
in patients with locally recurrent prostate cancer after radiation therapy.
Materials and Methods:
This was a prospective study, and informed consent was obtained from all patients. 
Ten consecutive patients with histopathologically proved recurrent prostate cancer 
after radiation therapy, without evidence of distant metastases, were treated while under 
general anesthesia in a 1.5-T MR unit. A urethral warmer was inserted. Cryoneedles 
were transperineally inserted under real-time MR imaging. Then, a rectal warmer 
was inserted. Ice ball growth was continuously monitored under MRI-guidance. 
Two freeze- thaw cycles were performed. Follow-up consisted of a visit to the urologist, 
measurement of prostate specific antigen level, and multi-parametric MRI at 3, 6, and 
12 months. Potential complications were recorded.
Results:
All patients were successfully treated. In one patient, the urethral warmer could not be 
inserted and the procedure was cancelled. Two months later, the procedure was 
successfully repeated. Another patient had urinary retention. Follow-up data were 
available for all patients. A local recurrence or remnant tumor was found in two 
patients after 6 months and in another patient after 12 months. These three patients 
underwent successful retreatment with MRI-guided focal cryoablation.
Conclusion:
MRI-guided focal cryoablation of recurrent prostate cancer after radiation therapy is 
feasible and safe. Initial results are promising; however, longer follow-up is needed 
and more patients must be studied.
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Introduction
Prostate cancer (PCa) is the most common form of cancer in the Western male 
population and has a significant socioeconomic impact (1). Approximately 25%–33% 
of patients with newly diagnosed PCa undergo a form of radiation therapy. Of these 
patients, 26%–52% develop biochemical signs of tumor recurrence within 5 years of 
treatment (2-4). Salvage prostatectomy is a frequently used therapy option in patients 
with recurrence after radiation therapy. However, high rates of incontinence (0%–67%) 
or rectal injury (0%–8%) (5,6) have led to the search for other salvage treatment 
options. For this reason, ablative techniques such as cryoablation, high intensity 
focused ultrasound, and photodynamic therapy have been explored. 
 Cryoablation, which is performed under transrectal ultrasonography (US) 
guidance, is an established treatment option for men with newly diagnosed or 
recurrent PCa (7). A large study describing the results of salvage whole-gland 
transrectal US–guided cryoablation in 279 patients reported an incontinence rate of 
10.2% and a rectourethral fistula rate of 1.1% (8). Other studies of cryoablation under 
transrectal US guidance have described comparable results (9-11).
 Cryoablation can be used for focal therapy purposes. To our knowledge, only 
one study has described transrectal US–guided salvage hemiablation of the prostate 
(12). To be able to perform focal therapy, however, accurate and adequate image 
guidance is a prerequisite. Transrectal US cannot provide accurate PCa localization 
and has major limitations in monitoring the ice ball during cryoablation owing to 
acoustic shadowing. Multi-parametric magnetic resonance imaging (MRI), which 
comprises T2-weighted, dynamic contrast material–enhanced, and diffusion-weight-
ed imaging, is currently the best technique available for PCa localization. For the 
detection and localization of PCa with multi-parametric MRI, areas under the receiver 
operating characteristic curve of, respectively, 0.94–0.98 (13-15) and 0.71–0.95 
(16-19) have been reported. During cryoablation, MRI-guidance enables accurate 
lesion targeting as well as three-dimensional monitoring of ice ball growth such that 
the PCa is treated completely and nearby critical structures are kept within a safe 
distance from the ice formation (20).
 Nonetheless, MRI-guided prostate cryoablation is very uncommon. Two studies 
described the first results of whole-gland MRI-guided cryoablation in patients with 
newly diagnosed PCa or local recurrence after radiation therapy or radical 
prostatectomy (21,22). 
 In contrast to the aforementioned studies, in which whole-gland MRI-guided 
cryoablation was used, herein we describe initial results with focal MRI-guided salvage 
cryoablation. The purpose of this study was to assess the feasibility of MRI-guided 
focal cryoablation in patients with locally recurrent PCa after radiation therapy.
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Materials and Methods
Preoperative Evaluation 
From May 2011 to February 2012, 10 consecutive patients (median age, 67 years; 
age range, 52–76 years) with histopathologically proved PCa recurrence after initial 
radiation therapy were enrolled in this study. Inclusion criteria were recurrent PCa 
after previous radiation therapy and no lymph node or bone metastases visible at 
MR imaging. Exclusion criteria were contraindications to MR imaging (eg, cardiac 
pacemakers, intracranial clips). After multidisciplinary consultation, MRI-guided focal 
cryoablation was preferred over salvage prostatectomy in these patients. 
 Our study was a prospective study. MRI-guided focal cryoablation is a legal 
clinical treatment in the Netherlands. Patients were informed about their treatment by 
the urologist and interventional radiologist. For these reasons, informed consent is 
not necessary according to Dutch law. Nevertheless, informed consent was retro-
spectively obtained from all patients to undergo treatment with MRI-guided focal 
cryoablation and to use their anonymized data for publication. 
 All patients underwent multi-parametric 3.0-T MR imaging (Magnetom Skyra; 
Siemens, Erlangen, Germany), which consisted of T2-weighted imaging, diffusion- 
weighted imaging, and dynamic contrast-enhanced imaging, with use of a pelvic 
phased-array coil to localize recurrent cancer (Figure 1) and to exclude bone and 
node metastases. Two radiologists (J.J.F. and J.O.B., with 9 and 18 years of experience 
in prostate MR imaging, respectively) evaluated in consensus the MR images with 
use of in-house–developed software. Tumor recurrences were identified purely on 
the basis of whether a focally enhancing region was seen on dynamic contrast- 
enhanced MR images, irrespective of the degree of enhancement, in combination 
Figure 1  Multi-parametric MR images obtained before cryoablation in 76-year-old man with 
histopathologically proved prostate cancer recurrence (Gleason score 3+4 = 7) 16 months 
after radiation therapy. Prostate is delineated by red line. Tumor is located in right peripheral 
zone (oval). A: Axial T2-weighted MR image of prostate (repetition time msec/echo time msec, 
5660/104; flip angle, 160°). B: Axial apparent diffusion coefficient map (2700/63). C: Axial dynamic 
contrast enhanced MR image (36/1.41; flip angle, 14°; temporal resolution, 3.5 seconds).
A B C
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with a low signal intensity on the T2-weighted images and/ or a low apparent diffusion 
coefficient on the diffusion-weighted images. Tumor sizes were measured in left-right, 
anteroposterior, and craniocaudal directions.
MRI-guided Cryoablation
All patients were admitted to the hospital the night before cryoablation. Patients were 
prescribed antibiotic prophylaxis (Ciproxin; Bayer, Leverkusen, Germany) for 14 days, 
starting on the day before cryoablation. Before undergoing cryoablation, patients 
were instructed to self-administer a cleansing enema to eliminate gas and remove 
feces. 
 All patients underwent treatment while under general anesthesia. After patients 
were anesthetized, a catheter was inserted into the urethra; this catheter was instantly 
exchanged for a urethral warmer. Patients were positioned in the lithotomy position 
on the imager table, and cushions were used to maintain proper positioning and to 
make the patient as comfortable as possible. A pelvic phased-array coil was placed 
over the patient’s pelvis. All procedures were performed by an interventional 
radiologist (J.J.F.) by using a cryoablation system (MRI SeedNet; Galil Medical, 
Yokneam, Israel) in a closed-bore 1.5-T MR system (Magnetom Avanto, Siemens). 
All imaging parameters are described in Table 1. 
Table 1  Image parameters for MRI-guided focal cryoablation
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Coronal
Sagittal
3:37
3:37
3:37
5000
5000
5000
107
107
107
150
150
150
0.7x0.6x3.0
0.7x0.6x3.0
0.7x0.6x3.0
160x160
160x160
160x160
n.a.
n.a.
n.a.
Balanced 
SSFP
IRT
Axial
Coronal
Sagittal 
n.a.
n.a.
n.a.
465.92
494.08
494.08
1.82
1.93
1.93
70
70
70
2.7x2.7x10
3.1x3.1x4.0
3.1x3.1x4.0
350x350
400x400
400x400
0.46
0.49
0.49
T1WI VIBE
Axial 0:50 4.81 1.96 6 1.3x1.3x2.5 250x250 n.a.
T2WI= T2-weighted MR imaging, SSFP= steady state free precession, T1WI= T1-weighted MR 
imaging, TSE= turbo spin echo, IRT= Interactive RealTime, VIBE=volumetric interpolated breath hold 
examination, TA = acquisition time, TR= repetition time, TE= echo time, FA= flip angle, FOV= Field of view
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A transperineal template attached to a flexible arm (Invivo, Schwerin, Germany) was 
placed against the perineum of the patient. The template was moistened with sterile 
gel to improve its visibility on the MR images. Next, for cryoneedle placement, 
T2-weighted images were acquired in three directions to relocalize the recurrent 
tumor and the transperineal grid. Cryoneedles (Ice- Seed and/or IceRod, Galil 
Medical) were transperineally inserted in the tumor by using real-time balanced 
steady-state free precession sequences. Images were directly projected onto a white 
screen in the MR room and obtained in at least two planes to get an accurate 
impression of the needle position. After placement of all cryoneedles, a rectal warmer 
was inserted into the rectum. Insertion was performed after cryoneedle placement to 
avoid puncturing the rectal warmer. Both warmers were continuously flushed with 
warm saline (43°C) to protect the urethra and the rectal wall from freezing. The number 
and type of cryoneedles inserted were dependent on the size of the recurrent tumor, 
which was determined with the multi-parametric MR images obtained during the 
preoperative evaluation. Both needle types have distinct freezing characteristics. 
After 10 minutes of freezing, the lethal zones of the IceSeed and IceRod are, 
respectively, 1 x 2 cm and 1.5 x 4 cm. 
 Ice ball growth was continuously monitored by using near-real-time T1- weighted 
volumetric interpolated gradient- echo MR imaging (Figure 2). The size and shape of 
the ice ball were regulated by adjusting the gas flow to each individual cryoneedle. 
The ice ball had to cover the total lesion, with a definite safety margin. This safety 
margin was limited by avoiding contact of the ice ball with the rectal wall. In total, 
two freezing cycles were performed. Each freezing period lasted 10 minutes or as 
long as the ice ball remained within a safe distance from the critical structures. This safety 
distance was determined by carefully monitoring the position of the hyperintense ice 
Figure 2  Images obtained during MR imaging–guided cryoablation in the same patient as in 
Figure 1. A: Axial T2-weighted MR image (5000/107; flip angle, 150°) shows cryoneedles in situ 
(circles). B-D: Axial T1-weighted MR images obtained with a volumetric interpolated gradient- 
echo sequence (4.81/1.96; flip angle, 6°) show growing ice ball (black signal intensity void), 
which eventually covered entire tumor.
A B C D
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ball rim. Active or passive thawing was continued until the cryoneedles were visible 
again on the MR images. The maximal size of the ice ball and the tumor–ice ball ratio 
were retrospectively determined. 
 The cryoneedles were removed after the second thawing period. The urethral 
warmer was flushed with warm saline for another 20–30 minutes to avoid strictures. 
Warming catheters were removed and a normal catheter was inserted into the urethra 
to avoid any temporary urinary incontinence or retention. This catheter was removed 
after 1 or 2 days. When patients returned to the nursing ward, they were asked to rate 
their pain during rest and while functioning according to a numeric rating scale from 
0 to 10, with 0 indicating no pain and 10 indicating unbearable pain. When no 
complications occurred, patients were discharged the day after the procedure. 
Patients were prescribed Movicolon (Norgine, Uxbridge, England) for 3 weeks to 
ease defecation and were advised to drink a substantial amount of water to rinse the 
bladder. Follow-up was performed at 3, 6, and 12 months and consisted of a visit to 
the urologist to check for complications (ie, urinary retention, incontinence, and rectal 
fistula), determination of prostate-specific antigen (PSA) level, and multi-parametric 
MRI of the prostate (Figure 3) to check for local recurrence and/or incomplete 
ablation. The protocol for follow- up multi-parametric MRI was the same as that used 
for pretreatment multi-parametric MRI, but without the bone and node protocol. The 
follow-up images were evaluated in the same way as the pretreatment MR images. If 
MR images were suspicious for tumor recurrence, MRI-guided biopsy of the 
suspicious area was performed.
 Total procedure and treatment times were annotated for all procedures. The total 
procedure time was defined as the time from the moment the patient entered the MR 
suite and anesthetization was started until the time anesthetization was ended and 
Figure 3  Multi-parametric MR images obtained in same patient as in Figure 1 at 3-month 
follow-up. Prostate is delineated by red line. Tumor is located in right peripheral zone (oval). 
A: Axial T2-weighted MR image (5660/104; flip angle, 160°) demonstrates tissue changes. 
B : Axial apparent diffusion coefficient map (2700/63) demonstrates higher apparent diffusion 
coefficients. C: Axial dynamic contrast-enhanced MR image (36/1.41; flip angle, 14°; temporal 
resolution, 3.5 seconds) demonstrates no enhancement in treatment area.
A B C
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the patient left the MR suite. Treatment time was defined as the time from the moment 
of the first MR image acquisition until the time the last image acquisition was finished. 
Results 
Feasibility
Ten patients were successfully treated with MRI-guided focal cryoablation. In one 
patient, the urethral warmer could not be inserted owing to perforation of the urethra 
and the procedure was cancelled. Two months later, the patient was successfully 
treated with MRI-guided focal cryoablation. 
 One of the patients had newly diagnosed PCa and had previously undergone 
radiation therapy for testis carcinoma. For this reason, other therapies (surgery or 
salvage radiation therapy) were not possible. Patient characteristics are shown in 
Table 2.1. The median tumor size was 20 mm (range, 9–40 mm) in the left-right 
direction, 11 mm (range, 8–22 mm) in the anteroposterior direction, and 17 mm 
(range, 11– 28 mm) in the craniocaudal direction. 
Procedure Characteristics
The median ice ball size was 36 mm (range, 26–53 mm) in the left-right direction, 30 mm 
(range, 16–42 mm) in the anteroposterior direction, and 44 mm (range, 27–58 mm) 
in the craniocaudal direction. The median ratio of ice ball size to tumor size was 1.7 
(range, 1.3–4.3) in the left-right direction, 2.1 (range, 1.3–4.3) in the anteroposterior 
direction, and 2.5 (range, 1.6–5.2) in the craniocaudal direction. 
 The median procedure time was 210.5 minutes (range, 179–375 minutes). 
The median treatment time was 133 minutes (range, 91–242 minutes). It is noteworthy 
that the first procedure had a procedure time and treatment time of, respectively, 375 
and 242 minutes and the last procedure lasted only 184 and 91 minutes (Table 2). 
When we consider the total procedure and treatment times of all procedures, there 
was a substantial learning curve during the 10 procedures (Figure 4).
 Eight patients went home the day after the procedure, so their hospital stay was 
2 days. Two patients were hospitalized for 3 days: The first patient stayed an additional 
night at his own request, and the fourth patient was observed for another night 
because he had urinary retention. All patients were satisfied with the treatment and 
did not experience much pain. After the procedure, the median pain score at rest 
was 1 (range, 0–8) and the median pain score during functioning was 2 (range, 0–8). 
 Apart from the one case of urinary retention, no other complications (eg, incontinence 
or fistula) were recorded. Procedure characteristics are shown in Table 2.2.
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Table 2.1  Patient characteristics
Patient Age 
(y)
Months  
between  
RT and cryo
Before RT Before cryoablation
Gleason 
Score
Stage PSA Gleason 
score
Stage PSA
1 65 80 7 n.a. 5.5 7 3b 2.7
2 66 52 6 3a 4 7 2 3.4
3a 67 n.a. n.a. n.a. n.a. 7 3 0.9
4 52 62 8 2-3 25 n.a. 2 8.7
5 68 76 6 1c 9 n.a. 2 8.4
6 71 55 8 3 19 9 2 7.2
7 60 119 8 2c 18 10 2 4
8 76 16 6 3a 14.6 7 2 7
9 67 30 7 1c 48 7 3b 3.1
10 68 24 7 2 12 n.a. 2 3.6
aPatient with newly diagnosed PCa and previous RT for testisca. n.a.= not available.
Table 2.2  Procedure characteristics
Patient No. of
cryo- 
needles
Procedure  
time
(minutes)
Treatment 
time
(minutes)
Complications Hospitalization
(days)
1 4 375 242 None 3
2 3 300 138 Perforation of  
the urethra
2
3 2 240 128 None 2
4 4 255 143 Urine retention 3
5 2 179 93 None 2
6 2 180 131 None 2
7 4 217 135 None 2
8 2 186 94 None 2
9 3 204 140 None 2
10 3 184 91 None 2
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Follow-up
Follow-up data are given in Table 3. After 3 months, PSA levels in eight patients 
decreased and multi-parametric MRI showed no presence of recurrent tumor. The 
PSA level increased in patients 8 and 10; however, multi-parametric MRI showed no 
local recurrence. In patient 8, the increase in PSA level was explained by a recent 
urinary tract infection. In patient 10, the increase in PSA level was only minimal and 
the urologist decided to pursue an expectative policy. Two patients had urinary 
retention and had to catheterize themselves once a day. Hematospermia (n = 1), 
hematuria (n = 1), and perineal pain (n = 1) were also reported. 
 After 6 months, the PSA level in patient 8 did not decrease, and, in the meantime, 
additional computed tomographic (CT) and bone scans were obtained to check for 
distant metastases. The bone scan was negative, but the CT scan showed an 
enlarged parailiacal lymph node on the left side. The patient started hormonal therapy 
(bicalutamide), and the PSA level decreased substantially. 
 Furthermore, two patients had a local recurrence at 6-month follow-up, and in 
both patients this was demonstrated by an increased PSA level and suspicious MR 
images and was histopathologically proved with MRI-guided biopsy. Both patients 
had a local recurrence just cranial to the previously treated area. When we retrospec-
tively examined the MR images acquired during the cryoablation procedure, it was 
found that both treatments had been too conservative because the ice ball did not 
cover the entire tumor. Both patients underwent repeat MRI-guided cryoablation. 
After 3 months, their PSA levels decreased and multi-parametric MRI showed no 
Figure 4  The procedure and treatment times per patient showing our learning curve.
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local recurrence. After 6 months, the PSA level was slightly increased in one patient, 
but multi-parametric MRI showed no local recurrence. The results of 6-month 
follow-up in the other patient are not yet known. 
 In patient 4, urinary retention was caused by a urethral stricture. This stricture was 
surgically removed. After surgery, the patient had to catheterize himself twice a day. 
In patient 9, multi-parametric MRI showed some contrast enhancement just lateral to 
the treatment zone. This area was sampled for biopsy under MRI-guidance, and no 
tumor recurrence was found. Four months after treatment, patient 10 died of causes 
unrelated to PCa. 
 In four patients, the results of 12-month follow-up are known. In three patients, 
the PSA level was stable and multi-parametric MR images were not suspicious for 
Table 3  Follow-up data
Patient 3 Months 6 months 12 Months
PSA 
(ng/mL)
MP-MRI PSA
(ng/mL)
MP-MRI PSA
(ng/mL)
MP-MRI
1 2.2 No recurrence 2.9a Recurrence, 
confirmed with 
MRGB 
n.a. n.a.
2 0.5 No recurrence 0.5 No recurrence 0.7 No recurrence
3 0.3 No recurrence 0.1 No recurrence 0.1 No recurrence
4 2.6 No recurrence n.a. No show 8.2 Recurrence, 
confirmed with 
MRGBa
5 1.3 No recurrence 1.4 No recurrence 1.6 No recurrence
6 5.9 No recurrence 6.4 No recurrence - -
7 0.1 No recurrence 3.0a Recurrence, 
confirmed with 
MRGB
- -
8 20.2 No recurrence 24.3 n.a. - -
9 1.1 No recurrence 1.5 MRI suspicious 
for tumor 
recurrence, 
MRGB negative
- -
10 4.0 No recurrence n.a. n.a b
n.a.= not available. 
aPatient had local recurrence and was treated again with MR-guided focal cryoablation
bPatient died of causes unrelated to prostate cancer
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tumor recurrence. Multi-parametric MRI of the third patient showed a local recurrence, 
which was proved with MRI-guided biopsy. This patient is now scheduled for repeat 
treatment with MRI-guided focal cryoablation.
Discussion
In this study, we demonstrated the feasibility of MRI-guided focal cryoablation in 
patients with recurrent PCa after radiation therapy. Eight patients were discharged 1 
day after the procedure, and nine patients did not have major complications. Patients 
who undergo salvage radical prostatectomy after radiation therapy are often 
hospitalized for 8–14 days (23). 
 A true comparison between the results of our study and those of other studies is 
difficult because of the different patient characteristic groups (newly diagnosed vs. 
local recurrence after radiation therapy or radical prostatectomy) and treatment styles 
(whole gland vs. focal). In one study, whole-gland MRI-guided prostate cryoablation 
was performed in eight patients with newly diagnosed PCa and three patients with 
local recurrence after radiation therapy with use of a wide-bore 1.5-T MR unit (21). 
Four to seven cryoneedles were used per patient. One major complication was 
reported: a rectal fistula that spontaneously healed after 3 months. Some minor 
complications, such as hematuria (n = 1), urinary tract infection (n = 1), scrotal pain 
(n = 1), and transient dysuria and urinary retention (n = 3), were reported as well. The 
mean hospitalization time was 5 days (range, 3–13 days). In another study, 12 patients 
with local recurrence of PCa after radical prostatectomy were treated in a 1.5-T wide 
bore MR unit. Two to five cryoneedles were used and two to three freeze-thaw cycles 
were performed per patient. No immediate complications were seen. However, within 
3 months, one patient had urinary retention and two patients had local recurrence 
contiguous to the urethra (22).
 The above-mentioned studies differ from our study in one important aspect: 
Whole-gland treatment was used in those studies and focal treatment was used in 
our study. Only the lesion, with a certain safety margin around it, was ablated. By 
applying focal treatment, we aimed to keep to a minimum complications such as 
incontinence, impotence, and rectal fistula formation. In addition, as a consequence 
of focal ablation, fewer needles (2–4) were needed per patient. Probably for the same 
reason, the hospitalization time was shorter as well (2–3 days). When comparing our 
results with those from a study describing transrectal US–guided salvage hemiablation 
of the prostate (12), our results were more consistent. In that study, two to four 
cryoneedles were used per patient and two to four freeze-thaw cycles were performed. 
Patients were discharged on the day of the procedure with a urine catheter in situ for 
2–5 days. Furthermore, the incontinence rate was 6.7%, the erectile dysfunction rate 
99
MRI-GUIDED FOCAL CRYOABLATION IN PATIENTS WITH RECURRENT PROSTATE CANCER 
6
was 60%, and no rectal fistulas were recorded. One patient harbored a residual 
carcinoma (12). 
 In our study, longer-term complications are known for only the first 6 months in 
all patients. The only intraprocedural complication was a perforation of the urethra 
after insertion of the urethral warmer. This was not described in other studies. PSA 
levels decreased substantially after 3 months. Multi-parametric MRI showed no 
evidence of local recurrence. Mild urinary retention was observed in two patients. A 
local recurrence was found in two patients after 6 months and in another patient after 
12 months. 
 One of the main reasons that MRI-guided cryoablation is suited for focal therapy 
is the potential for exact monitoring of the ice ball formation. Previous studies 
described the presence of a hyperintense border around the hypointense ice ball at 
fast T1-weighted imaging (24). This hyperintense rim is caused by shortening of the 
T1 in cooled but not yet frozen tissue (25,26). By carefully monitoring this edge, the 
exact ice ball can be monitored. In this way, the tumor can be focally treated and 
nearby critical structures such as the urethra, rectal wall, and neurovascular bundle 
can be avoided. An alternative approach to obtaining temperature information with 
use of MRI is to monitor the proton resonance frequency shift. However, to enable MR 
signal measurements from cooled tissue, the echo time must be shortened, which in 
turn decreases temperature accuracy. In addition, the proton resonance frequency 
method is seriously affected by susceptibility artifacts at the ice-tissue transition (27).
 Our study has a number of limitations. Foremost, this is a prospective study and 
there is no information yet on long-term outcomes. Furthermore, there was a 
considerable learning curve. In the earliest procedures, a lot of time was lost in 
determining the suitable workflow. In addition, a lot of time was spent preparing the 
diagnostic MR room for the procedure. Furthermore, all MRI-guided focal cryoablation 
procedures were performed in a 1.5-T MR system with a normal-sized bore (60 cm), 
which means that the amount of space for patient positioning and instrument handling 
is limited. Proper patient positioning was therefore essential. 
 For the purpose of creating more space for patient positioning and instrument 
handling and improving image quality, the possibility of performing MRI-guided 
cryoablation in a wide-bore MR unit should be explored. Other future steps will be to 
investigate the long-term follow-up of the treated patients, to optimize the workflow, 
and to perform MRI-guided cryoablation in combination with an MRI-compatible 
robot (28). Workflow optimization and robotic needle placement could further 
decrease the procedure and treatment times. 
 In conclusion, transperineal MRI-guided focal cryoablation of the prostate in 
patients with local recurrence after radiation therapy was feasible and safe. Although 
initial results are promising, longer follow-up is needed and more patients must be 
included.
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Abstract
Purpose:
To evaluate feasibility, adverse events, quality of life (QoL) and local cancer control 
after focal salvage MRI-guided cryoablation in patients with local radio-recurrent 
prostate cancer (PCa).
Materials and Methods:
A retrospective, single-center study was performed in 41 patients with radio-recurrent 
PCa who underwent MRI-guided cryoablation since May 2011 and a follow-up of ≥12 
months in December 2015. Feasibility and adverse events were reported with rates 
and description of adverse events. Surgical complications were classified according 
to the Clavien system. Validated questionnaires were used to observe functional 
outcomes and QoL before therapy and after 6 and 12 months. Cancer control was 
defined as no biochemical failure according to Phoenix-criteria and no other clinical, 
radiological or histopathological evidence for local or metastatic disease.
Results:
All procedures were technically feasible. The number of life-threatening adverse events 
(Clavien-grade 4) or complications needing intervention under general anesthesia 
(Clavien-grade 3b) was low, with respectively n=1 (2.4%) for both Clavien-grades. 
After 12 months, the ICIQ-SF- (p=0.001) and IIEF-5 scores (p=0.024) became 
significantly worse, indicating increased symptoms of incontinence and decreased 
erectile function, without compromising for QoL. Five patients developed metastases 
within 6 months and probably had micrometastatic disease at the time of treatment. 
After 12 months, 23 patients (59%) was disease free.
Conclusion:
Focal salvage MRI-guided cryoablation is feasible and shows a positive balance 
between adverse events, functional outcome, QoL and local cancer control. This 
treatment can be a reasonable alternative with low morbidity to salvage radical 
prostatectomy in properly selected patients, however longer follow-up is needed.
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Introduction
Biochemical recurrent prostate cancer (PCa) after a form of radiotherapy occurs in 
approximately 26 – 52% of the patients (1,2). At present, salvage radical prostatectomy 
(SRP) can be performed. This has a curative intent, but is technically challenging 
because of radiation-induced fibrosis and shrinkage of the prostate gland, resulting 
in high rates of urinary incontinence and rectal injury (0-28% and 0-67%, respectively) 
(3,4) which severely affects the quality of life (QoL). In addition, surgery is contra-
indicated in most patients because of their age and comorbidities. Androgen 
deprivation therapy (ADT) can be an alternative. However, the latter is unattractive 
because of its temporary effect, which can lead to an increased risk of cardiovascular 
mortality, skeletal fracture and a decreased QoL (5,6).
 Minimally invasive treatments have emerged to serve as alternative salvage 
therapy, i.e. high intensity focused ultrasound, high-dose brachytherapy and cryoablation. 
In case of a local recurrence, these minimally invasive treatments can be applied 
locally (7-13). Goal is to treat localized tumors only to obtain local cancer control, 
while sparing the rest of the prostate to minimize potential morbidity. 
 Accurate image guidance is of utmost importance to enable focal treatment. In 
contrast to ultrasound imaging, magnetic resonance imaging (MRI) is able to accurate 
lesion targeting and treatment monitoring during cryoablation. Iceball growth can be 
monitored in real-time and in multiple planes, such that damage to adjacent critical 
structures as the rectal wall can be minimized (14). 
 Additionally, local recurrent disease after radiotherapy may be very suitable for 
focal treatment, because it is more often unifocal (72% vs. 17%) and has a smaller 
cancer volume (0.68 cm3 vs. 3.43 cm3) compared to primary PCa (15,16). Furthermore, 
local recurrences are likely to occur at the same site as the index lesion before radio- 
therapy (17,18). 
 Because of aforementioned reasons, we hypothesized that focal salvage 
MRI-guided cryoablation might be a reasonable alternative to SRP, particularly in 
patients with significant chance on comorbidities but with a significant life expectancy. 
 The purpose of this study was to evaluate the feasibility, adverse events, QoL 
and local cancer control in patients with locally recurrent PCa after radiotherapy 
using this novel treatment approach. 
Materials and Methods
Study design and patients
Between May 2011 and December 2015, 53 consecutive patients underwent focal 
salvage MRI-guided cryoablation of the prostate after previous radiotherapy. Before 
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treatment, all patients underwent multi-parametric (mp) MRI to localize the recurrence. 
Furthermore, all were negative on macroscopic metastatic screening with abdominal 
and pelvic MRI. 
 In December 2015, 41 patients had a follow-up of ≥12 months and were included 
in our study. No restrictions were placed on characteristics of pre-radiotherapy 
cancer, PSA levels, Gleason score and stage of recurrent disease. All patients gave 
written informed consent for being treated with MRI-guided focal cryoablation and 
using their anonymized data for publication. A small study describing the feasibility 
results of the first 10 patient was published before (19).
Procedures
Patients were admitted to the hospital on the night before (n=19) or a few hours 
before treatment (n=22). Antibiotic prophylaxis (Ciprofloxacine) was started for 14 days 
at admission and they were given a cleansing enema to remove faeces. 
 All patients were treated in a closed-bore 1.5 (n=14) or 3 Tesla (T) (n=27) 
MR-system (Magnetom Avanto/Skyra; Siemens, Erlangen, Germany) under general 
anaesthesia. Cryoablation was performed with a MRI-compatible cryoablation device 
(MRI-SeedNet; GalilMedical, Yokneam, Israel). Multiple cryoneedles (IceSeed/IceRod; 
GalilMedical) were transperineally inserted in the tumor under MRI-guidance (X). 
During freezing, the urethra and the rectal wall were protected with warming catheters. 
In every patient two freeze-thaw cycles were performed. After the procedure, 
the cryoneedles and the rectal warmer were removed and the urethral warmer was 
Figure 1  Study flow diagram.
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changed for a Foley-catheter. Patients were discharged the day after treatment. 
When spontaneous voiding was not possible, a Foley-catheter was inserted for 
another 7 days. 
 Follow-up consisted of urological checkups at 1-3, 6 and 12 months for PSA-tests 
and adverse event reporting. At 3, 6 and 12 months a multi-parametric MRI was 
performed to determine local cancer control. MRI-guided biopsies were performed 
when a tumor suspicious region was seen on the multi-parametric MRI. Since August 
2013, the multi-parametric MRI at 12 months was followed by 2-3 targeted MRI-guided 
biopsy samples of the edge/rim of the ablated region to confirm treatment success with 
histopathology. If biopsies were positive, patients could be retreated with MRI-guided 
cryoablation after multidisciplinary consensus with the urologist, radiation- oncologist 
and interventional-radiologist. From January 2013, patients were asked to complete 
validated questionnaires (IPSS, ICIQ-SF, IIEF-5 and FACT-P (20-23) ) before therapy 
and after 6 and 12 months. 
 Primary outcomes of the study were feasibility, adverse events, functional outcome 
and QoL. Feasibility and adverse events were reported with rates and description of 
adverse events. Surgical complications were classified according to the modified 
Claviensystem for reporting surgical complications (24). The IPSS (including the 
IPSS-QoL questionnaire) and ICIQ-SF were used to assess urinary function and to 
define the proportion of men who were leak-free (<1x/day urinary leakage). High 
IPSS, IPSS-QoL and ICIQ-SF scores indicated poor urinary functioning. The IIEF-5 
questionnaire was used to assess the potency, defined as being capable of having 
erectile function sufficient for penetration, as well as total IIEF-5 score. A low IIEF-5 
score indicated poor erectile function. QoL was assessed with FACT-P with summary 
measures of the FACT-Prostate score, FACT-General score and the Trial Outcome 
Index (TOI) score. High scores indicated a better QoL. 
 Secondary outcome of the study was to determine cancer control, which was 
defined as no biochemical failure according to the Phoenix criteria (PSA nadir+2) and 
no other clinical, radiological or histopathological evidence for local recurrent or 
metastatic disease. 
Statistical analyses
Missing values for individual questions were imputed based on known clinical data 
as was reported to the urologist. Because of the retrospective design of our study, not 
every patient filled in questionnaires at every time point. Data of all patients who filled 
in the questionnaires of at least one time point (n=32) were used in generalized -least-
squares analyses using unstructured covariance matrix for residuals to accommodate 
the repeated measurements. Outcomes were reported as point estimates with 
95% CIs to demonstrate level of precision. P-values <0.05 were considered 
significant. All statistical analyses were performed with SPSS (version 22). 
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Results 
In total, 41 men were included in our study. One patient died 5 months after 
MRI-guided cryoablation from an unrelated stomach perforation. Another patient was 
diagnosed with colon cancer 2 months after MRI-guided cryoablation and was 
therefore excluded from follow-up analyses. Patient characteristics of all patients are 
summarized in Table 1. 
Table 1  Baseline demographics
Patients (N=41)
(Median(IQR))
Age (years) 67.0 (64.0-72.0)
Type of Radiotherapy 
External Beam Radiation Therapy
Brachytherapy
External Beam Radiation Therapy AND Brachytherapy
25 (61.0%)
15 (36.6%)
1 (2.4%)
Time between RT and MRI cryo (months) 71.5 (51.3-95.0)
Pre RT characteristics
PSA (ng/mL)
Gleason
≤5
6
7
8
unknown
Tumor stage
T1c – T2
T3
unknown
12.1 (7.1-20.1)
4 (9.8%)
15 (36.6%)
12 (29.3%)
8 (19.5%)
2 (4.9%)
19 (46.3%)
19 (46.3%)
3 (7.3%)
Pre MRI cryo characteristics
PSA (ng/mL)
Gleason
6
7
8
9
10
unknown
Tumor stage
T2
T3
Prior ADT use
4.1 (2.7-7.7)
5 (12.2%)
16 (39.0%)
6 (14.6%)
5 (12.2%)
1 (2.4%)
8 (19.5%)
29 (70.7%)
12 (29.3%)
16 (39.0%)
RT = Radiotherapy, PSA= Prostate specific antigen, ADT = Androgen deprivation therapy
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Forty-four procedures were performed in 41 patients. Three patients (7.3%) were 
re-treated with focal salvage MRI-guided cryoablation because of local recurrent 
(N=2) or remnant (N=1) tumor after the first procedure. 
Feasibility and adverse events
Due to the inability of inserting the urethral warmer in the second patient, one 
procedure was cancelled and successfully repeated two months later. All other 
procedures were technically feasible and no per-procedural complications were 
reported. Procedure characteristics are summarized in Table 2.
 Thirty-eight patients (92.3%) were discharged the day after treatment. The very 
first patient was monitored for two nights and went home without complications. Two 
patients had to stay one more night because of acute urinary retention. They went 
home with a Foley-catheter for 7 days. Six months later one of them developed a 
urethral stricture, which was surgically treated (Clavien grade (CG)3b). Afterwards he 
needed clean-intermittent catheterization (CIC). One patient was hospitalized for 
17 days because he suffered from a myocardial infarction the day after the cryoablation. 
This man had a medical history of cardiac disease and underwent cardiovascular 
interventions before. Although it is not clear that the myocardial infarction was related 
to the cryoablation procedure, it was defined as a CG4a complication. 
Seven other patients had acute urinary retention and six of them went home with a 
Foley-catheter for 7 days (CG1). In the seventh patient placement of a Foley-catheter 
was not possible due to prostate swelling and a temporary suprapubic catheter was 
placed (CG3a). None of the patients experienced voiding problems after removal of 
the catheter. 
 In the months after cryoablation patients reported urinary retention needing CIC 
once a day (n=2, CG1); urinary incontinence, needing several pads per day (n=2, 
CG1); stress/urge incontinence (n=9, CG1); a perineal wound, which resolved after 2 
weeks (n=1, CG1) and urinary tract infections needing antibiotics (n=4, CG2). After 
three months, one patient developed a rectovesical fistula which was conservatively 
Table 2  Procedure characteristics
Median(IQR)
Total anaesthetic time (min) 183.5 (165.0-208.0)
Procedure time (min) 108.0 (95.0-126.0)
Number of cryoneedles 3.0 (2.0-4.0)
Hospitalization (days) 2.0 (1.0-2.0)
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treated by placing a suprapubic catheter (CG3a). Another patient developed a 
rectoprostatic fistula one month after treatment. By way of precaution a Foley-catheter 
was placed for a few weeks (CG1). This fistula resolved spontaneously within 3 months. 
All adverse events defined according to the Clavien classification are summarized 
in Table 3. 
Functional outcome and quality of life
All scores are summarized in Table 4 and shown in figure 2 and 3. Between baseline 
and 12 months, ICIQ-SF scores increased significantly (p=0.001), indicating increased 
symptoms of incontinence. One year after treatment IIEF-5 scores decreased significantly 
(p=0.024), indicating decreased erectile function. No significant differences were seen 
in IPSS or IPSS-QoL-scores, when comparing baseline scores with scores 12 months 
after treatment. 
 At baseline, 91.3% (21/23) of the patients was leak-free this declined to 60.9% 
(14/23) after 12 months. Before treatment, ten patients reported to have erections 
sufficient for penetration, after 12 months 6/10 (60.0%) preserved their potency. 
Between baseline and 12 months, no significant differences were seen in the QoL 
scores for total FACT-P, FACT-G and TOI. 
Cancer control
The cancer control outcomes are summarized in Figure 4. Six months after MRI-guided 
cryoablation 32 patients (82.2%) were disease free. One patient developed biochemical 
recurrence, another patient was diagnosed with local disease based on suspicious 
findings on multi-parametric MRI. Five patients were diagnosed with metastatic disease. 
Table 3   Complications classified according to the modified Clavien System for 
reporting surgical complications after the first MRI-guided cryoablation 
procedure (N=41)
Grade Definition N=41 (%)
1 Any deviation from normal post-operative course 24 (58.5)
2 Complications needing intravenous medication or antibiotics 4 (9.8)
3a Complications needing intervention under local anesthesia 2 (4.9)
3b Complications needing intervention under general anesthesia 1 (2.4)
4a Life-threatening: Single organ dysfunction 1 (2.4)
4b Life-threatening: Multiple organ dysfunction 0 (0)
5 Death of the patient 0 (0)
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These patients may have had micro-metastases at the time of their MRI-guided 
cryoablation, which were not detected during pre-treatment imaging. 
 Between 6 and 12 months, another nine patients showed disease progression. 
Two of them were diagnosed with metastases, seven other patients were diagnosed 
with local disease. After multidisciplinary consensus with the urologist, radiation- 
oncologist and interventional-radiologist, three of them were retreated with 
MRI-guided cryoablation. Consequently, 23 patients (59.1%) were disease-free after 
12 months.
 MRI-guided biopsy of the edge of the ablation zone was performed in fifteen 
patients after 12 months. Although the multi-parametric MRI showed no signs of 
disease, vital tumor cells were found in 3/15 (20%) patients. In one patient only a few 
individual tumor cells were found. In the other two patients, maximal tumor lengths of 
respectively 1 and 4 mm were found.
Table 4   Results validated questionnaires for functional outcome and quality  
of life
N=32 Baseline 6 Months 
after treatment
12 Months 
after treatment
Baseline vs.
 12 Months
Mean 
(95% CI)
Mean 
(95% CI)
Mean 
(95% CI)
 p- value
(95% CI  
for difference)
IPSS 9.4 
(7.0 – 11.7)
9.7 
(6.7 – 12.6)
10.1 
(7.7 – 12.5)
0.595
(-2.0 – 3.4)
IPSS-QoL 1.8 
(1.4 – 2.1)
1.8 
(1.4 – 2.2)
1.9 
(1.5 – 2.3)
0.532
(-0.4 – 0.7)
ICIQ-SF 1.6 
(0.6 – 2.7)
4.6 
(3.1 – 6.1)
4.7 
(3.1 – 6.4)
*0.001
(1.3 – 4.9)
IIEF-5 10.8 
(7.7 – 13.9)
9.9 
(7.3 – 12.4)
7.7 
(5.4 – 10.0)
*0.024
(-5.9 – -0.5)
FACT-P 130.8 
(126.6 – 135.1)
126.2 
(119.8 – 132.7)
126.3 
(120.0 – 132.5)
0.101
(-10.2 – 1.0)
FACT-G 92.3 
(89.1 – 95.5)
89.2 
(84.1 – 94.4)
90.4 
(86.0 – 94.9)
0.263
(-5.3 – 1.5)
TOI 88.6 
(85.5 – 91.7)
85.7
(81.3 – 90.1)
85.4 
(81.4 – 89.4)
0.118
(-7.2 – 0.9)
*statistically significant
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Figure 2  Results validated questionnaires for functional outcome measured with the IPSS, 
IPSS-QoL, ICIQ-SF and IIEF-5 questionnaires. Plots show mean values (bars) with a 95% CI 
(whiskers). Two-tailed p-values were calculated comparing baseline and 12 month mean scores. 
* indicates p<0.05.
Figure 3  Results for quality of life outcome measured with the FACT-P questionnaires. Plots 
show mean values (bars) with a 95% CI (whiskers). Two-tailed p-values were calculated comparing 
baseline and 12 month mean scores. * indicates p<0.05.
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Learning curve
Three patients were retreated with MRI-guided cryoablation. Retrospective analysis 
of the intra-operative MR images showed that in 1 out of 3 patients the iceball did not 
cover the complete tumor. This happened in our first patient and may be attributed to 
our learning process of conservative treatment in the first few procedures to minimize 
potential morbidity.
Figure 4  Kaplan-Meier curve for cancer control according to the Phoenix-criteria for bio - 
chemical disease free survival in combination with any clinical, radiological or histopathological 
evidence for local or recurrent disease.
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Discussion
We demonstrated that focal salvage MRI-guided cryoablation in patients with PCa 
recurrence after radiotherapy is feasible and appeared to show a positive balance 
between adverse events, functional outcome, QoL and cancer control in this patient 
group. The number of life-threatening adverse events or complications needing 
intervention under anesthesia was low (n=2, 4.9%). After 12 months, only the ICIQ- 
SF- and IIEF-5 scores became significantly worse, without compromising the QoL. 
 A low complication and morbidity rate is also reported by other studies on focal 
salvage therapy (7-13,25,26). This is in contrast to the results after SRP. A systematic 
review averaging the results of 24 studies, reported an incontinence rate of 50%, 
bladder neck stricture in 26%, rectal injury in 5% and rectal fistula in 2.4% of the 
patients after SRP (27). Although our reported complication rate is lower, our study is 
not directly comparable to these previous studies. Reasons for this are different 
inclusion criteria and therefore diverse patient groups; other treatment methods (i.e. 
hemiablation vs. focal ablation); and distinct definitions for functional outcomes and 
disease free survival. Furthermore, some studies lump functional outcomes along 
with complications instead of reporting objective validated questionnaire-based 
data. Preferably baseline, short-term and long-term urinary, sexual and bowel function 
should be ascertained utilizing patient-reported questionnaires. However, these 
instruments are underutilized and data are sparse. In our study these data were 
collected in most of the patients, yielding unique information. 
 Proper patient selection is important when performing focal salvage therapy. In 
contrast to previous focal salvage studies, we also included patients with extracapsular 
extension and/or seminal vesicle invasion. This might have had a negative influence 
on our cancer control rate, because these patients have a higher chance of developing 
metastatic disease. Micrometastatic disease was probably present in five patients at 
the time of their MRI-guided cryoablation, because they were diagnosed with 
metastatic disease within 6 months after treatment. This was not detected during 
pre-treatment imaging, probably because the current radiological work-up to detect 
distant metastases is not sensitive enough (28). Recently, lymphotropic nanoparti-
cle-enhanced MRI became available in our centre. This technique has shown high 
sensitivity (65-92%) and specificity (93-98%) in detecting PCa lymphnode metastases 
(28) and may improve our patient selection (29). 
 In this study multi-parametric MRI was used to detect and localize clinically 
significant disease after radiotherapy. It has shown a 95% negative predictive value in 
detecting local recurrences (30). Despite this, tumor could have been missed or 
treated incompletely, because it was not (completely) visible on the MR images. 
 Currently, there is no consensus how to determine biochemical failure after 
salvage focal therapy (31). Phoenix- and Astro-criteria were originally developed to 
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define biochemical failure after radiotherapy. They are not suitable and validated for 
use after focal therapy, because part of the prostate remains untreated and the 
mechanism of cell death is different between cryoablation and radiotherapy. Because 
of the absence of a validated definition, in this study Phoenix-criteria were used in 
combination with any clinical, radiological or histopathological evidence for local 
recurrent or metastatic disease to determine cancer control. Despite this combined 
approach influenced our cancer control rate in a negative way, we think it has surplus 
value, since 4 patients who did not had biochemical failure yet were diagnosed with 
recurrent disease after multi-parametric MRI and targeted MRI-guided biopsy. For 
this reason we recommend to perform targeted biopsy of the rim of the ablation zone. 
 Limitations of our study were the relative small number of patients, its retrospective 
design and incomplete follow-up. Although our results are encouraging, more 
patients are currently included and longer follow-up is performed. Unfortunately, our 
patient follow-up was not complete. In the start-up period of MRI-guided cryoablation, 
functional outcomes and complications were not systematically reported with 
validated disease-specific questionnaires in this patient group. This led to an 
incomplete follow-up and hampered an objective comparison in functional outcome 
and QoL before- and after treatment. This is also reason that not all patients underwent 
MRI-guided targeted biopsy of the area treated with cryoablation. 
 Future steps will be to study which prognostic factors (i.e. PSA, stage, ADT use, 
etc) have influenced our outcome. This will improve the current patient selection 
methods and we might be able to determine the true value of this treatment for the 
right patient group. Next to this, trials combining MRI-guided cryoablation with 
adjuvant therapy or immunotherapy could be developed. 
 In conclusion, focal salvage MRI-guided cryoablation is feasible and shows a 
positive balance between adverse events, functional outcome, QoL and cancer 
control. It may be a reasonable alternative to SRP in properly selected patients, 
however longer follow-up is needed.
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CHAPTER 8
Abstract
Purpose:
To correlate treatment effects of MRI-guided focal laser ablation in patients with 
prostate cancer with imaging using prostatectomy as standard of reference.
Materials and Methods:
This phase I study was approved by the Institutional Review Board. Three weeks prior 
to prostatectomy, five patients with histopathologically proven, low/intermediate 
grade prostate cancer underwent transrectal MRI-guided focal laser ablation. Per 
patient only one ablation was performed to investigate the effect of ablation on the 
tissue rather than the effectiveness of ablation. Ablation was continuously monitored 
with real-time MR temperature mapping and damage-estimation maps were 
computed. A post-ablation high-resolution T1-weighted contrast-enhanced sequence 
was acquired. Ablation volumes were contoured and measured on histopathology 
specimens (with a shrinkage factor of 1.15), T1-weighted contrast-enhanced images 
and damage-estimation maps, and were compared.
Results:
A significant volume correlation was seen between the ablation zone on T1-weighted 
contrast-enhanced images and the whole-mount histopathology section (r=0.94, 
p=0.018). The damage-estimation maps and histopathology specimen showed a 
correlation of r=0.33 (p=0.583). On histopathology, the homogeneous necrotic area 
was surrounded by a reactive transition zone (1–5mm), showing neovascularisation 
and an increased mitotic index, indicating increased tumor activity.
Conclusion:
The actual ablation zone was better indicated by T1-weighted contrast-enhanced 
than by damage-estimation maps. Histopathology results highlight the importance of 
complete tumor ablation with a safety margin. 
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Introduction
With an estimated amount of 233,000 newly diagnosed patients and 29,000 deaths 
in the United States in 2014, prostate cancer (PCa) has a significant impact on society 
(1). The treatment choice for low- to intermediate grade PCa patients ranges between 
active surveillance and whole-gland therapies, i.e. radical prostatectomy or 
radiotherapy. However, these treatments come with morbidity and influence quality of 
life (QoL) (2,3). For instance, 2 years after treatment, 3.2–9.6% of these patients 
experiences urinary leakage and 56–78.8% suffers from erectile dysfunction (2,3).
 Focal therapy is an emerging alternative treatment option for low- to intermediate 
grade PCa (4). It is a strategy, by which the overtreatment burden of the current 
prostate cancer pathway could be reduced and QoL is preserved. The challenge is 
to treat the tumor entirely, sparing normal prostate tissue, especially near the 
neurovascular bundles and the urethral sphincter, and to minimize potential morbidity. 
Currently, focal therapy should be performed under strict surveillance because of its 
experimental nature. 
 Various minimal invasive techniques, such as cryoablation, high intensity focused 
ultrasound (HIFU), irreversible electroporation and focal laser ablation (FLA), have 
been used to perform focal therapy in PCa patients (5-11). All these techniques have 
their own characteristics and are still evolving. At this moment there is no consensus 
which technique is optimal for focal therapy.
 Of the available minimal invasive focal therapy techniques, MRI-guided FLA is 
considered a promising option, since it is fast, creates a sharply defined ablation 
zone, is minimally invasive for the patient and can be performed under local 
anesthesia in an outpatient setting. During this treatment, a laser fiber is inserted into 
the tumor and the tissue is irreversibly damaged and destroyed when its temperature 
increases >60°C. The total ablation process takes only a few minutes. Furthermore, 
repeat treatments, as well as secondary radical treatment, are still possible. MRI- 
guidance appears essential in FLA and might prove to be the only imaging modality 
for correct targeting of the index lesion, facilitating accurate fiber placement, real-time 
monitoring of the ablation with the help of temperature mapping, and verification of 
complete tumor ablation (12). 
 To date, only a few studies reported on MRI-guided FLA in PCa patients (5,13-17). 
Moreover, the latter include feasibility studies using small sample sizes and follow-up 
≤1 year. One study validated the ablation volume after ultrasound-guided FLA, but 
used a laser system with a different wavelength (12). Validation of MRI-guided FLA is 
required, before it can gain acceptance as treatment option for patients with low- to 
intermediate grade PCa. Insight into the actual treatment zone can be obtained by 
comparing per-procedural MRI temperature maps and histopathology correlation. 
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Therefore, the goal of our study was to correlate treatment effects of MRI-guided FLA, 
rather than treatment success. Before radical prostatectomy, patients underwent 
MRI-guided FLA as extra treatment. One single ablation per tumor was performed to 
investigate the effect of the ablation on the tissue, rather than the effectiveness of the 
treatment. Damage-estimation maps derived of MRI temperature maps, post ablation 
T1-weighted contrast-enhanced (T1wCE) MR images and histopathology specimens 
were used to correlate the expected and actual size of the ablated region. 
Materials and Methods
Patients
The study was approved by the Institutional Review Board (IRB) and all patients 
provided written informed consent. Between May 2012 and November 2013 five 
patients were included. A study flow diagram is shown in Figure 1. 
Inclusion criteria were men with newly diagnosed and histopathologically proven 
PCa with a prostate specific antigen (PSA) level of ≤20 ng/mL, Gleason score ≤7, 
stage ≤T2b, no previous treatment for PCa, scheduled for radical prostatectomy and 
a tumor lesion visible on the anatomical T2-weighted (T2w) and/or diffusion-weighted 
images (DWI) of the diagnostic multi-parametric MRI and located more than 2 cm of 
the neurovascular bundle. Patients with contra-indications to MRI or MRI-guided 
FLA, nodal or metastatic disease or an estimated Glomerular Filtration Ratio <40 mL/
min/1.73m2 were excluded.
MRI-guided focal laser ablation
Patients were prescribed antibiotic prophylaxis (ciprofloxacin) for three days, starting 
on the day before the FLA procedure. All procedures were performed on a 3 Tesla 
MRI scanner (TrioTIM, Siemens, Erlangen, Germany) and a 980 nm diode laser 
system (Visualase, Houston, Texas, USA). Patients were positioned head first in 
prone position on the scanner table. A pelvic phased-array coil was placed over the 
patient’s pelvis. 
Figure 1  Study flow diagram.
Patient
included 
Transrectal
MRI-guided
FLA 
Radical
Prostatectomy 
3 Weeks 
End follow-up
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Table 1   MRI parameters
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Laserablation protocol (Siemens MAGNETOM Triotim)
T2WI TSE
Axial 3:35 4570 101 120 1.1x0.8x3.0 256x256 n.a. n.a.
DWI EPI
Axial 3:08 2500 64 n.a. 2.0x2.0x4.0 256x212 50/500/800 n.a.
True-Fisp SSFP
Axial
Sagittal
8.9
7.5
4.48
4.48
2.24
2.24
70
70
1.1x1.1x3.0
1.1x1.1x3.0
280x280
280x280
n.a.
n.a.
n.a.
n.a.
T2WI HASTE
Axial 0:18 1800 94 120 1.7x1.3x3.0 340x276 n.a. n.a.
T-MAP n.a. 65 20 30 2.0x1.0x5.0 260x260 n.a. 4.95
T1WI TSE
Axial 3:02 700 11 150 1.0x0.8x3.0 200x200 n.a. n.a.
Detection protocol 3T (Siemens MAGNETOM Skyra)
T2WI TSE
Sagittal
Axial
Coronal
2:53
4:15
1:57
5590
5660
4320
101
104
101
160
160
160
0.6x0.6x3.0
0.5x0.5x3.0
0.6x0.6x3.0
180x180
192x192
192x192
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
DWI EPI
Axial 4:08 3200 63 n.a. 2.0x2.0x3.0 256x240 50/500/800/ 
calc1400
n.a.
DCE 3D PD
Axial 2:13 800 1.53 14 1.5x1.5x3.0 192x192 n.a. n.a
GE
Axial 2:34 36 1.41 14 1.5x1.5x3.0 192x192 n.a 3.5
TA= Acquisition time; TR= Repetition time; TE= Echo time; FA= Flip angle; FOV= Field of view; T2WI= 
T2-weighted imaging; TSE= Turbo spin echo; DWI= Diffusion weighted imaging; EPI= Echo planar im-
aging; SSFP= Steady-state free precession; HASTE= Half-fourier acquisition single-shot turbo-spin echo; 
T-MAP= Temperature map; T1W1= T1-weighted imaging; DCE= Dynamic contrast-enhanced imaging; 
PD= Proton density; GE= Gradient echo.
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A gadolinium filled needle guide was inserted in the rectum and attached to a 
MRI-compatible device (DynaTrim, Invivo, Schwerin, Germany), originally developed 
for MRI-guided biopsies. The procedure was performed under local anaesthetic 
block administered by bilateral injections of lidocain between the base of the prostate 
and the seminal vesicles (18). Anatomical T2w-images and DWI were acquired to 
re-identify the MRI visible lesion. All image parameters are shown in Table 1. TrueFisp 
images were acquired in two directions, to direct the needle guide to the lesion. After 
correct alignment, a 14-gauge catheter with a titanium trocar was inserted through 
the needle guide. Once the catheter was positioned inside the tumor, the titanium 
trocar was replaced by the laser fiber. The tip of the laser fiber was unsheathed from 
Figure 2  Images of a 67 year old male with a Gleason score 3+4=7 in his right transition zone. 
A: Real-time MRI temperature map acquired during FLA. B: Anatomical MRI of the prostate 
(delineated in blue) with the Arrhenius-based damage-estimation zone as orange overlay. C: 
Post-ablation axial T1-weighted contrast-enhanced image. The prostate is delineated in blue 
and the non-enhancing necrotic tissue in green. D: Whole-mount H&E stain of the prostate. The 
necrotic tissue is delineated in green, the perinecrotic tissue in yellow and vital tumor in blue.
A
C
B
D
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the catheter to enable immediate contact with the tumor tissue. Proper laser fiber 
placement was verified in two ways: first by acquiring a TrueFisp sequence and 
second by applying laser energy on a reduced power level. This was insufficient to 
cause thermal injury, however this was visible on the MRI thermometry images.
 The FLA procedure was continuously monitored with MRI thermometry images, 
acquired every five seconds in a single plane through the laser fiber. Relative 
temperatures were calculated based on the proton resonance frequency (PRF) 
method (19) and the temperature maps (Figure 2A) were shown on the integrated 
standalone Visualase workstation connected to the MRI scanner. If the temperature 
at a certain point increased too much, this was immediately visible. Next to the 
temperature maps, a damage-estimation zone with an estimation of the final ablation 
area was shown as an overlay on the anatomic MRI (Figure 2B). This zone was 
computed using the Arrhenius model for thermal tissue ablation (20). 
 Tumors were only partially ablated, because per patient only one ablation was 
performed in order to investigate the effect of the ablation on the tissue rather than 
the effectiveness of the treatment. Immediately after ablation an axial T1-weighted 
contrast-enhanced (T1wCE) sequence was performed (Figure 2C) to assess the size 
of the ablation. Hereafter the laser fiber and the needle guide were removed. Patients 
were discharged when voiding was uncomplicated. 
 Procedure time was determined as from the moment the first MRI sequence was 
started until the last MRI sequence was finished, including T2w and DWI to re-identify 
the tumor and T1wCE-images to assess ablation zone. Three weeks after FLA, 
patients underwent open radical prostatectomy, performed by one of two oncologic 
urologists with 25 and 9 years experience.
Histopathology work-up
The resected prostate specimens were fixed overnight in 10% neutral-buffered 
formaldehyde and coated with ink. Transverse wholemount step sections were 
created at four mm intervals in a plane parallel to the axial plane used to perform the 
T1-weighted sequence. Apical and basal slices were additionally sliced in the sagittal 
plane and all sections were embedded in paraffin. Tissue sections of five μm were 
stained with hematoxylin-eosin (H&E) (Figure 2D). The presence and extent of 
necrotic tissue, the surrounding perinecrotic zone with reactive changes and vital 
tumor were annotated on the glass-cover with the tissue section. Additionally, 
immunostaining for CK8/18, CD31 and Ki67 was performed to demonstrate the 
presence of epithelial damage, vascular damage and mitotic activity. The mitotic 
index was determined as the mean count of Ki67-positive nuclei in five microscopic 
fields of 1 mm2 surface area (20x objective Zeiss Axioskop). The fields for counting 
were taken in the first 1 mm zone of vital tumor (or pre-existing prostatic ducts) directly 
adjacent to the necrotic area; at the opposite tumor invasion front; and in the center 
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of the tumor more than two mm distant from the perinecrotic or invasion front areas. 
For tumor tissue, areas were chosen with the same Gleason score and duct density. 
All measurements were independently performed by two genitourinary pathologists 
with 22 and 27 years experience.
Data analyses 
By assuming that the final form of the Arrhenius-based damage-estimation zone 
would be ellipsoid, the length and width of the final zone were measured and the 
ablation volume was calculated. Two experienced prostate MRI radiologists with 
11 and 3 years experience blinded for the final pathology results, contoured the ablation 
zone per slice in the post-ablation T1wCE images. The ablation area per slice was 
calculated by the PACS software and multiplied with the slice thickness to determine 
the total ablation volume. Volumes of the necrotic zone annotated on the histopathology 
slices were measured using an in-house developed software program. A factor of 
1.15 was used to correct for tissue shrinkage (21).
 Per patient, the volume of the ablated tissue in the prostate specimen was 
compared with the volume of the Arrhenius-based ablation zone and the volume of 
the ablation zone in the T1wCE images by calculating the ratios between the volumes. 
Statistical comparisons were made by calculating the Pearson correlation coefficient 
r and corresponding two-tailed p-values with SPSS Statistics version 20. P-values 
<0.05 were considered statistically significant. 
Results 
Patients
MRI-guided FLA was safe and feasible to perform and no immediate complications 
were encountered. All patients were discharged one hour after treatment.
 Two days after the MRI-guided FLA procedure one patient was hospitalized for 
one week with urosepsis. He was treated with intravenous antibiotics and underwent 
radical prostatectomy three weeks later. All radical prostatectomies were uncomplicated. 
The surgeons did not report any difficulties due to previous laser ablation. All patient- 
and procedure characteristics are shown in Table 2.
Histopathological outcomes
The results of both pathologists were in concordance. A homogeneous necrotic area 
surrounded by a reactive perinecrotic zone of variable thickness (1–5 mm) was 
observed in all patients. The perinecrotic zone showed pre-existing prostatic tissue 
and tumor tissue with reactive changes such as increased proliferation activity, neo-
vascularisation with doubling of the microvessel density, and a variable lymphocytic 
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infiltrate. Pre-existing prostate tubuli showed reactive epithelial changes such as 
increased proliferation rate and squamous metaplasia. In the CK8/18 stain tumor 
tubuli were less resistant to the ablation than pre-existing tubuli, which extended 
further into the necrotic or perinecrotic zone. However, as indicated by the Ki67 stain, 
the tumor cells showed an increased mitotic index in the perinecrotic area (Figure 
3A), adjacent to the ablation area (Table 3). An increased mitotic activity was also 
seen at the tumor invasion front (Figure 3B). The mitotic index was lowest in the center 
of the tumor (Figure 3C). 
Table 2   Patient and procedure characteristics.
Patient Age 
(yr)
PSA 
(ng/mL)
Biopsy
Gleason 
Score
Procedure 
time (min)
Ablation 
time 
(s)
Laser 
energy 
(W)
Final 
Gleason 
score
1 66 9.3 3 + 4 84 91 12 3 + 2 (+4)
2 58 8.5 3 + 3 118 91 10 3 + 3
3 67 10.2 4 + 3 100 91 10 3 + 4
4 60 16.2 3 + 4 74 81 15 3 + 4 (+5)
5 70 5.7 3 + 2 59 73 11 3 + 2 (+5)
Figure 3  Histopathologic Ki67 stained slides in an axial plane through the prostate showing 
mitotic activity represented by the brown nuclei. A: Perinecrotic area, showing increased mitotic 
activity. B: Tumor invasion front, showing lower mitotic activity than in the perinecrotic area. C: 
Center area of vital tumor, showing hardly any mitotic activity.
A B C
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Volume comparison
All volumetric measurements per individual patient are shown in Table 4. The median 
ratio between the necrotic volume of the ablated tissue in the prostate specimen (Fig 2D) 
and the measured ablation volume on the T1wCE MR images (Fig 2C) was 0.80 
(range, 0.40–2.09) and showed a significant volume correlation with a Pearson 
correlation coefficient of r=0.94 (p=0.018). The ablation volumes on the damage- 
estimation maps (Fig 2B) derived from the MRI temperature maps (Fig 2A) were 
always larger than the ablation zones in the T1wCE MR images and the necrotic 
volumes in the histopathology specimen. The median ratios between those volumes 
were respectively 8.77 (range 2.11–21.47) and 5.85 (range 1.39–25.39), and were 
poorly correlated; r=0.26 (p=0.673) and r=0.33 (p=0.583). 
Table 3   Mitotic index per area.
Area Mean MI / mm2 (range)
Paranecrotic tumor 99.3 (54-127)
Mid tumor 17.75 (1-58)
Opposite invasion front 41.3 (7-121)
Paranecrotic normal 85.0 (25-215)
Mid normal (BPH) 6.4 (1-21)
MI=Mitotic Index. BPH=Benign Prostate Hyperplasia.
Table 4  Volumetric measurements per individual patient.
Patient Volume on  
damage estimation 
map (cm3)
Volume on  
T1wCE images  
(cm3)
Volume on histopathology 
specimen corrected with 
shrinkage factor 1.15 (cm3)
1 3.30 1.00 1.06
2 1.93 0.22 0.00
3 3.65 0.17 0.43
4 2.32 1.10 1.67
5 1.46 0.12 0.06
T1wCE = T1-weighted contrast-enhanced images
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Discussion 
The most important finding of our study was revealed by the histopathology results. 
All prostate specimens showed a homogeneous necrotic area surrounded by a 
perinecrotic area of 1–5 mm thickness. However, in this perinecrotic area, reactive 
changes were seen as for example neovascularization and an increased mitotic 
index. These processes were also seen in the tumor invasion front, were the tumor 
invades in healthy tissue.
 Stimulated growth of surviving tumor cells after incomplete thermal ablation 
(cryoablation or radiofrequency ablation) was observed earlier in renal tumor cells 
(22) and after incomplete radiofrequency ablation in liver cells (23). Increased tumor 
cell proliferation was seen up to the end of the studies, respectively 14 and 21 days 
after ablation and is possibly caused by tissue damage, increased hypoxia, increased 
presence of heat-shock proteins and inflammatory cells directly adjacent to the 
ablation area (22). The clinical consequences of this effect remain unclear; in the 
worst-case scenario it could facilitate tumor outgrowth; in the best case scenario the 
effect is only a temporary reaction on the cellular damage caused by the ablation. 
More research is needed to gather additional insight into these processes. 
Nevertheless, this highlights the importance of complete tumor ablation. To achieve 
this, the lesion size should be clearly visualized for optimal treatment planning and 
targeting and larger safety margins around the tumor should be employed. Le Nobin 
et al (24) correlated visible prostate tumor volume on MRI with histology and 
concluded that a 9 mm noncapsular and a 3 mm capsular treatment margin should 
be applied to ensure complete tumor treatment. 
 In other ablate-resect studies, performed with MRI-guided FLA in canine 
prostates (25), in patients after ultrasound-guided FLA (12) or after HIFU (26,27), 
increased tumor activity was not observed. A possible explanation for this difference 
might be that in all these studies the total tumor was ablated and a less extensive 
histopathology workup without Ki67-staining was performed. 
 The damage-estimation zones obviously overestimated the final necrotic volume 
in T1wCE images as well as the histopathology specimen, and showed poor volume 
correlation. The non-enhancing tissue on the post-ablation T1wCE MRI gave a better 
indication of the final histopathologic necrotic volume and showed significant volume 
correlation. One of the reasons for the inconsistency between the ablation zones 
shown on the damage-estimation maps and the obtained ablation volumes in the 
histopathology specimen is probably due to tissue heterogeneity within the prostate. 
Furthermore, during laser ablation tissue properties, as for example thermal 
conductivity, change due to temperature increase. Other factors which could have 
influenced the MRI-temperature mapping and thus the Arrhenius-based calculated 
volumes on the damage-estimation maps are the spatial resolution of the sequence, 
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patient movement during scanning and the inability of measuring temperature 
changes in extraprostatic fat tissue (28). 
 A study of Oto et al. demonstrated successful MRI-guided FLA in nine patients 
(5). Urinary and sexual function did not significantly change afterwards. After six 
months, patients underwent MRI-guided biopsy of the ablation zone. In 78% no 
tumor was found and in 22% a Gleason Score 6 was found. In another study by Lee 
et al, 23 patients were treated (16). Thirteen of them underwent targeted biopsy of the 
ablation zone, only one (7.7%) showed residual disease and was re-treated. No 
changes were seen in urinary or sexual functioning six months after the procedure. 
Recently, the results of 25 patients were reported by Lepor et al (17). Three months 
after treatment the mean PSA decreased of 40% and post-ablation MRI did not show 
signs of residual or recurrent PCa. Furthermore, targeted biopsy of the ablation zone 
was performed, and in 96% of the ablation zones no evidence of residual PCa was 
found. 
 This study had several limitations. Firstly, a small sample size was used. Because 
of the large patient burden without any personal gain, the IRB committee considered 
it not ethical to treat more than five patients. Secondly, the volume calculations might 
have been influenced by several factors inherent to the difficulty of optimally matching 
MR images with pathology slices. Prostate specimens were sliced in a parallel plane 
used to perform the T1wCE-sequence, however there might have been small 
deviations. Furthermore, a tissue shrinkage factor of 1.15 was used for all cases, 
because it was not possible to determine the shrinkage per individual prostate. 
Thirdly, due to the small patient numbers and long inclusion period, a learning curve 
was present, especially influencing the procedure time. 
 Future steps will be to evaluate urinary and sexual function, quality of life and 
oncological efficacy of MRI-guided FLA in patients with low- to intermediate grade 
PCa on a longer term and large patient population. 
 In conclusion, this study demonstrated the importance of complete tumor 
ablation with a certain safety margin. Furthermore, T1wCE images are more reliable 
in determining the final ablation zone than damage-estimation maps derived from 
MRI temperature maps. Although initial results are promising, longer and thorough 
follow-up is needed to prove long-term outcome of this novel technique.
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General discussion 
Focal therapy as treatment option for localized (recurrent) PCa is an increasingly 
popular and rapidly developing area (1-9). The purpose of my thesis was to develop 
and optimize MRI-guided focal therapy in patients with localized (recurrent) prostate 
cancer. 
 In chapter 2 and 3 we evaluated the use of an MR-compatible remote-controlled 
manipulator to perform MRI-guided prostate biopsies. The conclusion of chapter 2 
was that the manual technique was more suitable to perform MRI-guided biopsies 
than the robotic technique, even though the results for accuracy and speed were 
comparable. This was mainly caused by the extended technical effort needed when 
performing the robotic technique. Because of the size of the robot, precise patient 
positioning was of utmost importance and consequently time-consuming. In case 
the patient and the robot were not positioned correctly, the whole setup did not fit 
inside the MR-bore, or the range of motion of the robot was restricted. These results 
led to the development of the second-generation remote-controlled manipulator with 
a smaller size (chapter 3). It was concluded that this device was feasible, safe, 
efficient and fast to use as an aid during MRI-guided prostate biopsies. The next step 
is to determine the accuracy of this remote-controlled manipulator. In the future this 
technique could also be combined with an automated real-time needle-guide 
tracking sequence (10), to speed up the procedure time even more. This special MRI 
sequence automatically recognizes the position of the needle guide and aligns the 
imaging plane with the needle guide in nearly real time. 
 Since accurate needle placement and treatment planning play an important role 
in image-guided focal therapy it is expected that remote-controlled manipulators will 
increasingly be used for this, since these are assumed to be more accurate and 
faster than humans. The device described in chapter 3 has been used successfully 
for several times during MRI-guided focal laser ablation to guide the laser applicator 
to the correct position.
 In chapter 4 we concluded that laser ablation and (high intensity) focused ultrasound 
were the most promising focal therapy options to perform with MRI-guidance. 
Nevertheless, the studies reported in this thesis are discussing cryoablation and 
laser ablation, the most important reason for this was simple; these two treatment 
options were available in our hospital. 
 Initially, cryoablation was not considered the most optimal technique to perform 
MRI-guided focal therapy. The main reason for this was that MR temperature mapping 
is at present not possible for temperatures below 0°C. Iceball formation is visible on 
real-time MRI, although the temperature gradient within the ice ball is not measurable. 
Since cryoablation is only lethal when tissue temperatures below -20°C are reached, 
the volume of the ice ball does not match the volume of tissue necrosis (11). As a 
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consequence, MRI-guided focal cryoablation is possible, but a safety margin of 
several millimeters should be applied. 
 In chapter 5 it was concluded that the hyperintensive signal rim visible around 
the iceball in the T1-weighted MR images represented cooled but non-frozen tissue. 
This information was quite valuable during MRI-guided focal cryoablation in patients, 
because initially we considered this rim as frozen tissue. With this newly acquired 
knowledge, larger iceballs could be generated without risk of damaging adjacent 
healthy tissue. Recently, a study was published demonstrating the feasibility and 
accuracy of 3D MR thermometry of frozen tissue with the help of ultrashort echo 
times in a clinical 3T MR scanner (12). Temperatures of -40°C could be measured with 
an acceptable accuracy. These experiments were performed in ex-vivo muscle tissue 
and should first be validated in-vivo before its applicable in clinical practice. When it 
turns out to be useful in patients, the temperature gradient within the iceball can be 
visualized and smaller safety margins around the iceball could be applied.
 In chapter 6 we discussed the safety and feasibility of MRI-guided focal 
cryo ablation as salvage treatment option for patients with a local recurrence after 
previous radiotherapy and in chapter 7 the 12-month follow-up results were presented. 
It was concluded that focal salvage MRI-guided cryoablation was feasible, safe and 
showed a positive balance between adverse events, functional outcome, quality of 
life and local cancer control. It may be a reasonable alternative to salvage radical 
prostatectomy in properly selected patients, however longer follow-up is needed.
 In our hospital, focal MRI-guided cryoablation is mainly offered as salvage 
treatment option for patients with locally radio-recurrent prostate cancer. In general, 
patients with a local recurrence after previous radical prostatectomy are less eligible 
for focal cryoablation. In these patients the bladder usually occupies the place 
created by the resected prostate, leaving limited space to position the cryoneedles 
and to create an iceball without harming adjacent structures as for example the 
bladder and the rectal wall. However, every patient’s eligibility to be treated with 
MRI-guided salvage focal cryoablation should be determined by examining the local 
anatomy with MRI.
 MRI-guided focal cryoablation can be performed as primary treatment as well, 
however, MRI-guided focal laser ablation is in our opinion more suitable for this. This 
technique is more refined because it can create smaller, sharper demarcated lesions 
and can be guided with MR temperature mapping. In chapter 8 we described the 
results of our phase I study where patients with newly diagnosed prostate cancer 
underwent MRI-guided focal laser ablation 3 weeks before their scheduled radical 
prostatectomy. This trial demonstrated the importance of complete tumor ablation 
with a certain safety margin and that the actual ablation zone was better indicated by 
T1-weighted contrast-enhanced images than by damage estimation maps. 
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The next step is to examine urinary and sexual function, quality of life and oncological 
efficacy after MRI-guided focal laser ablation. Therefore, a phase II study is started in 
our center, evaluating the aforementioned parameters. Twenty patients will undergo 
MRI-guided focal laser ablation as primary treatment. Follow-up consists of PSA-level 
measurement every three months and a multi-parametric prostate MR examination 
after 1 – 3 weeks, 6 and 12 months. After 12 months, MRI-guided biopsy of the edge 
of the ablation zone was performed. Next to this, at baseline and every three months 
after treatment, patients were asked to fill in validated questionnaires to monitor 
post-treatment morbidity, i.e. impotence (IIEF) and incontinence (IPSS), and 
health-related quality of life (EQ-5D).
 The research in this thesis provides data regarding the development and 
improvement of two types of MRI-guided focal therapy: cryoablation and laser ablation. 
Our initial results are encouraging, however long term evidence is needed to further 
validate these initial results. 
Future perspectives
At the moment, focal therapy is still considered experimental. A recently published 
systematic review by Valerio et al, concluded that focal therapy is safe and has low 
negative impact on continence and potency (13). The next step is to evaluate 
oncological outcome and cost-effectiveness against standard of care. 
 When (MRI-guided) focal therapy will be acknowledged as treatment for localized 
prostate cancer, it is anticipated that many patients will opt for focal therapy instead 
for active surveillance or radical prostatectomy. Especially patients where surgery is 
not an option because of the patient’s health status; patients who choose for active 
surveillance because they are afraid of potential complications after surgery; or 
patients who do not necessarily need surgery, but opt for radical prostatectomy 
because they cannot live with the psychological burden of having cancer; can benefit 
of (MRI-guided) focal therapy. Only in the Netherlands, it is estimated that each year 
hundreds of patients with newly diagnosed prostate cancer would be eligible to 
undergo focal therapy. 
 According to a report published in 2014 by the Dutch Cancer Society (KWF 
kankerbestrijding) describing the data of patients with prostate cancer in the period 
of 2007 – 2011 in the Netherlands, 22% and 23% of the patients were diagnosed with 
respectively low- or intermediate risk prostate cancer (14). With an incidence of 
approximately 11.000 men newly diagnosed with prostate cancer each year, 
respectively 2400 and 2500 men are diagnosed with either low- or intermediate risk 
prostate cancer. More than 1200 patients (>50%) in the low-risk group and 800 
(>32%) in the intermediate-risk group, prefer active surveillance above treatment. 
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Radical prostatectomy is performed in 532 (22%) and 759 (30%) of the low- and inter-
mediate-risk group patients. These are the patients potentially eligible for focal 
therapy.
 In the group of patients with prostate cancer recurrence this is harder to estimate. 
In the Netherlands 36% of the patients (±4000) with newly diagnosed localized 
prostate cancer is treated with radiotherapy (14). Biochemical recurrent prostate 
cancer after previous radiotherapy occurs in approximately 26-52% of the patients 
(15,16). Not all of these people will be eligible for salvage focal therapy, nevertheless 
there is a large potential. The guidelines of the Dutch Society for Urology (Nederlandse 
Vereniging voor Urologie (NVU)) describe that whole-gland salvage treatment has a 
high risk on severe toxicity and therefore should be offered with caution. Focal 
salvage therapy in considered as a promising technique with only a small chance on 
toxicity. 
 This potential market did not pass by unnoticed. Since a few years, several 
centers in the Netherlands offer different types of focal therapy, despite the fact that 
focal therapy is still considered experimental according to the Dutch guidelines for 
prostate cancer. Patients with localized prostate cancer can be focally treated with 
high-intensity focused ultrasound (HIFU) in Bergen op Zoom, high-dose rate (HDR) 
brachytherapy in Utrecht, irreversible electroporation (IRE) in Amsterdam, cryoablation 
in Nijmegen and Groningen or with laser ablation in Nijmegen. Most of these 
treatments are offered within a clinical trial. All these techniques currently offered are 
largely related to device and skill availability in the various centers rather than 
established guidelines for the best type of focal therapy. 
 However, as discussed before, not all of these techniques are suitable to be 
performed with MRI-guidance. This might be a major disadvantage, because when 
performing focal therapy, the perfect balance should be found between treating the 
entire tumor with a certain safety margin around it and sparing the adjacent healthy 
tissue. MRI with its excellent soft tissue contrast for accurate tumor detection and 
localization, its ability to monitor the treatment in real-time in several imaging 
orientations and to map the tissue temperature can make a valuable contribution to 
this and should be used when possible. 
 Despite the large potential patient group, proper patient selection is of utmost 
importance. More research needs to be performed to evaluate which patients will 
gain the most by focal therapy and how these patients should be selected (17). 
Multi-parametric MRI of the prostate combined with targeted MRI-guided biopsies 
should become standard of care before selecting patients for focal therapy. This can 
be extended with advanced imaging as for example nano-MRI or 68Ga-PSMA 
scanning to exclude for small nodal or distant metastases (18,19). Other questions 
have raised regarding the follow-up after focal therapy. For example, which 
instruments (ie. PSA, biopsy, imaging) should be used and how often PSA level 
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should be monitored, but a standard definition for biochemical recurrence does not 
exist yet. In the last consensus meeting MRI was universally recommended as a tool 
for follow-up after focal treatment (20,21). 
 To conclude, the results presented in this thesis are only the beginning, a lot of 
research needs to be done. With focal therapy, we are at the start of a new era in 
prostate cancer treatment and MRI will play an important role in patient selection, 
treatment monitoring and follow-up.
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Summary – MRI-guided focal therapy in patients  
with localized (recurrent) prostate cancer
Focal therapy as treatment option for localized (recurrent) prostate cancer is an 
increasingly accepted and fast developing area. Multi-parametric MR imaging is able 
to accurately detect and localize prostate cancer. MRI-guidance enables targeting of 
the tumor, treatment monitoring and to map the tissue temperature in real-time. The 
purpose of this thesis was to develop and optimize MRI-guided focal therapy in 
patients with localized (recurrent) prostate cancer. 
 In Chapter 2 the accuracy and speed of an in-house developed, pneumatic controlled 
MR-compatible manipulator as an aid to perform MRI-guided prostate biopsies were 
evaluated. In 13 consecutive prostate biopsy procedures, the targeting error, biopsy error 
and target displacement were calculated to evaluate the accuracy and the manipulation- 
and procedure time were determined to evaluate the speed. These results were compared 
with a matching population of patients who underwent manual MRI-guided prostate 
biopsy. Both techniques showed comparable results for mean targeting error and mean 
target displacement. Mean biopsy error was larger for the robot, although not significant. 
When using the robotic technique, the manipulation time was shorter, however the 
procedure time was longer. Although comparable results regarding accuracy and speed 
were found, the extended technical effort of the robotic technique make the manual 
technique – currently – more suitable to perform MRI-guided biopsies. 
 Chapter 3 evaluated the feasibility of a 2nd generation MR-compatible remote- 
controlled manipulator for MRI-guided prostate biopsies. Twenty patients with at least 
one cancer suspicious region underwent MRI-guided prostate biopsy with the help 
of the remote-controlled manipulator. Complications were classified according to 
the modified Clavien system for reporting surgical complications. For evaluation of 
the workflow, procedure- and manipulation times were recorded. All cancer 
suspicious regions were reachable. It was concluded that using a MR-compatible 
remote- controlled manipulator as an aid, is a feasible, safe, fast and efficient way to 
biopsy suspicious prostate lesions with a minimum number of biopsies per patient.
 In Chapter 4 a review describing different MRI-guided therapy options was 
performed. Furthermore, their feasibility for focal therapy in prostate cancer patients 
was investigated. It discussed cryoablation, laser ablation, (high intensity) focused 
ultrasound, radiofrequency ablation, microwave ablation and low- and high-dose-rate 
brachytherapy as possible options for MRI-guided focal therapy of the prostate. 
MRI-guided laser ablation and MRI-guided focused ultrasound were considered to 
be the most promising options for focal treatment of the prostate in patients with prostate 
cancer. Other techniques, i.e. microwave ablation, cryoablation and radiofrequency 
ablation, were for several and different reasons, less suitable for MRI-guided focal 
therapy of the prostate.
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Chapter 5 correlated the T1-weighted MR image contrast around an iceball during 
MRI-guided cryoablation with temperature. First, the normalized signal intensity was 
correlated with the temperature in a phantom study. The cryoablation iceball 
appeared as a sharply delineated signal void with a 2.2±0.2mm wide hyperintense 
rim in the T1-weighted MR images. This rim represented cooled but nonfreezing 
tissue temperatures. Hereafter the same T1-weighted imaging sequence was 
acquired in ten consecutive patients undergoing MRI-guided focal cryoablation to 
assess the in vivo appearance of the iceball. In these clinical procedures the same 
image contrast was observed as during the phantom study. It was concluded that 
monitoring of this hyperintense rim around the iceball could be helpful to preserve a 
safety margin between the iceball and critical structures as for example the rectal wall 
to protect them from freezing. 
 Chapter 6 evaluated the feasibility of MRI-guided focal cryoablation in patients 
with prostate cancer recurrence after radiotherapy. Ten patients with histopathologically 
proven, locally recurrent prostate cancer after radiation therapy, without evidence of 
distant metastases, were treated while under general anesthesia in a 1.5T MR 
scanner. Follow-up consisted of PSA level measurement, a visit to the urologist and 
multi-parametric MRI at 3, 6, and 12 months. All patients were successfully treated. 
The urethral warmer could not be inserted in one patient and the procedure was 
cancelled. Two months later, the procedure was successfully repeated. Another 
patient suffered from urinary retention. Follow-up data were available for all patients. 
Remnant tumor or a local recurrence was found in 2 patients after 6 months and in a 
third patient after 12 months. These three patients underwent successful retreatment 
with MRI-guided focal cryoablation. We concluded that MRI-guided focal cryoablation 
was feasible and safe. 
 In Chapter 7 the short term (12 months) follow-up results after MRI-guided 
cryoablation for 41 patients were presented. Feasibility and adverse events were 
reported with rates and description of adverse events. Surgical complications were 
classified according to the Clavien system. Validated questionnaires were used to 
observe functional outcomes and QoL before therapy and after 6 and 12 months. 
Cancer control was defined as no biochemical failure according to Phoenix-criteria 
and no other clinical, radiological or histopathological evidence for local or metastatic 
disease. All procedures were technically feasible. The number of life-threatening 
adverse events (Clavien-grade 4) or complications needing intervention under 
general anesthesia (Clavien-grade 3b) was low, with respectively n=1 (2.4%) for both 
Clavien-grades. After 12 months, the ICIQ-SF- (p=0.001) and IIEF-5 scores (p=0.024) 
became significantly worse, indicating increased symptoms of incontinence and 
decreased erectile function, without compromising for QoL. Five patients developed 
metastases within 6 months and probably had micrometastatic disease at the time of 
treatment. After 12 months, 23 patients (59%) was disease free.
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Chapter 8 correlated the treatment effects of MRI-guided focal laser ablation in 
patients with newly diagnosed prostate cancer with MR imaging using prostatectomy 
as standard of reference. Five patients underwent MRI-guided focal laser ablation as 
extra treatment, three weeks before their radical prostatectomy. Damage estimation 
maps, based on MR thermometry imaging, and T1-weighted contrast-enhanced 
images acquired directly after laser ablation were compared with the whole-mount 
histopathology specimen. Between the ablation zone on T1-weighted contrast- 
enhanced images and the whole-mount histopathology section a significant volume 
correlation was seen (r=0.94, p=0.018). The damage-estimation maps and histopathology 
specimen showed a correlation of r=0.33 (p=0.583). On histopathology, the 
homogeneous necrotic area was surrounded by a reactive transition zone (1–5mm), 
showing neovascularisation and an increased mitotic index, indicating increased 
tumor activity. This result highlighted the importance of complete tumor ablation with 
a safety margin.
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Nederlandse samenvatting – MRI-geleide focale 
therapie in patiënten met gelokaliseerd 
(recidiverend) prostaatcarcinoom
De belangstelling naar focale therapie als behandeloptie voor gelokaliseerd (recidiverend) 
prostaatcarcinoom wordt steeds groter. Het is een snel groeiend gebied waarin veel 
ontwikkeling plaatsvindt. Eerder is al gebleken dat we met multi-parametrische 
MRI in staat zijn om prostaatcarcinoom nauwkeurig te detecteren en lokaliseren. 
Daarnaast kunnen we MR beelden gebruiken om de tumor aan te prikken, toezicht te 
houden op de behandeling en de weefseltemperatuur te controleren.Het doel van 
dit proefschrift was om MRI-geleide focale therapie verder te ontwikkelen en te 
optimaliseren voor patiënten met gelokaliseerd (recidiverend) prostaatcarcinoom.
 In Hoofdstuk 2 evalueerden we de nauwkeurigheid en snelheid van een 
pneumatisch aangedreven, MR-compatibele robot tijdens een MRI-geleide prostaat-
biopsie. Dit werd gedaan in dertien opeenvolgende procedures waarin MRI-geleid 
prostaatbiopten werden genomen met de MR-compatibele robot. Om de nauw- 
keurigheid te bepalen, werden de richtingsfout, de biopsie-afwijking en de laesie- 
verplaatsing berekend. De richtingsfout was gedefinieerd als de kortste afstand 
tussen het geplande naaldpad en de oorspronkelijke locatie van het verdachte 
gebied. Door het inbrengen van de biopsienaald kan de plaats van het verdachte 
gebied namelijk veranderen, dit werd de laesieverplaatsing genoemd. De biopsie- 
afwijking was gedefinieerd als de kortste afstand tussen de biopsienaald en de 
locatie van het verdachte gebied na het inbrengen van de biopsienaald. Verder werd 
tijdens elke procedure de manipulatie- en de totale proceduretijd bijgehouden. 
De resultaten hiervan werden vergeleken met een vergelijkbare groep patiënten die 
een manuele MRI-geleide prostaatbiopsie ondergingen. In beide procedures waren 
de gemiddelde richtingsfout en de gemiddelde laesieverplaatsing hetzelfde. 
De biopsie-afwijking was groter tijdens de procedures met de robot, maar dit was 
niet significant. De manipulatietijd was korter als de robot gebruikt werd, maar de 
totale procedure duurde langer. Ondanks dat de resultaten voor nauwkeurigheid en 
snelheid vergelijkbaar waren tussen beide soorten procedures, werd geconcludeerd 
dat de manuele biopsie procedure geschikter was voor het nemen van MRI-geleide 
prostaatbiopten. Dit omdat het opzetten en gebruiken van de robot op dat moment 
nog relatief veel tijd kostten. 
 Onder meer naar aanleiding van de eerder besproken resultaten en ervaringen 
met de robot werd een nieuwe robot ontwikkeld. In Hoofdstuk 3 werd het gebruik 
van deze tweede generatie, MR-compatibele robot besproken. In twintig patiënten 
met minstens één gebied verdacht voor prostaatcarcinoom werden MRI-geleid 
prostaat biopten genomen met behulp van de robot. Tijdens deze procedures werden 
de manipulatietijd, de totale proceduretijd bijgehouden. Eventuele complicaties 
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werden geclassificeerd volgens het Clavien-graderings systeem voor chirurgische 
complicaties. Het bleek dat alle verdachte gebieden bereikt konden worden met de 
robot en in 70% van deze gebieden werd prostaatcarcinoom gevonden. De mediane 
proceduretijd was ruim 36 minuten en de mediane manipulatietijd bedroeg bijna 6 
minuten. Er traden twee geringe complicaties op, die werden geclassificeerd als 
Clavien-grade 1. De conclusie van deze studie was dat de robot veilig gebruikt kon 
worden tijdens een MRI-geleide prostaatbiopsie en dat het een snelle en efficiënte 
manier is om MRI-geleid prostaatbiopten te nemen. 
 In Hoofdstuk 4 werd een literatuuroverzicht gegeven van verschillende behandel-
methodes die onder MRI-geleide uitgevoerd kunnen worden. Daarnaast werd 
gekeken of deze behandeltechnieken ook geschikt waren om focale therapie mee uit 
te voeren. Cryoablatie, laserablatie, gefocust ultrageluid, radio-frequente ablatie, 
microgolf ablatie en twee verschillende vormen van brachytherapie werden 
besproken als mogelijk opties voor MRI-geleide focale behandeling van de prostaat. 
MRI-geleide laserablatie en MRI-geleide gefocust ultrageluid werden gezien als de 
meest veelbelovende manieren om prostaatcarcinoom op een focale manier te gaan 
behandelen. De andere behandeltechnieken werden om verschillende redenen 
minder geschikt geacht. 
 Hoofdstuk 5 beschreef de correlatie tussen de temperatuur en de signaal-
intensiteit rondom een ijsbal zoals deze zichtbaar is op T1-gewogen MR-beelden. 
Eerst werd een fantoomstudie gedaan waarin de genormaliseerde signaalintensiteit 
werd gecorreleerd aan de temperatuur. De ijsbal, zoals deze ontstaat tijdens een 
cryoablatie, werd op T1-gewogen MR-beelden zichtbaar als een scherp afgrensbaar 
gebied zonder signaal met daaromheen een 2,2±0,2mm brede rand met hoog 
intens signaal. Deze rand vertegenwoordigde gekoeld, maar nog niet bevroren 
weefsel. Na deze fantoomstudie werden dezelfde T1-gewogen MR-beelden gemaakt 
in tien opeenvolgende patiënten die MRI-geleide focale cryoablatie ondergingen om 
hun prostaatcarcinoom te behandelen. Het doel hiervan was om te kijken of de ijsbal 
in een menselijk lichaam op dezelfde manier afgebeeld kon worden. Dit was 
inderdaad het geval; ook hier werd de ijsbal zichtbaar als een scherp afgrensbaar 
gebied zonder signaal omringd met een rand van hoog intens signaal. Door tijdens 
een MRI-geleide cryoablatie een veiligheidsmarge aan te houden tussen deze rand 
met hoge signaalintensiteit en belangrijke structuren zoals de urethra en het rectum, 
kunnen deze beschermd worden tegen bevriezingsschade.
 In Hoofdstuk 6 werd de haalbaarheid van MRI-geleide focale cryoablatie als 
behandeloptie voor patiënten met een recidiverend prostaatcarcinoom na eerdere 
radiotherapie besproken. Tien patiënten met een histopathologisch bewezen, lokaal 
recidief prostaatcarcinoom zonder bewijs voor metastasen, werden onder algehele 
anesthesie behandeld met MRI-geleide focale cryoablatie in een 1,5T MRI scanner. 
De patiënten kregen 3, 6 en 12 maanden na deze behandeling een multi-parametri-
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sche MRI scan, een PSA meting en ook brachten ze een bezoek aan de uroloog. Alle 
patiënten werden succesvol behandeld. In één patiënt was het niet mogelijk om de 
urethraverwarmer in te brengen, waarna de procedure werd geannuleerd. Twee 
maanden later werd de behandeling alsnog succesvol uitgevoerd. Eén patiënt had 
last van urineretentie en kreeg daarvoor tijdelijk een urinekatheter. In twee patiënten 
werd na 6 maanden een lokaal recidief of een tumorrest gevonden. In een derde 
patiënt werd dit na 12 maanden gevonden. Deze patiënten werden alle drie opnieuw 
succesvol behandeld met MRI-geleide focale cryoablatie. De conclusie van deze 
studie was dat MRI-geleide focale cryoablatie een haalbare en veilige behandeloptie 
is voor patiënten met een lokaal recidief prostaatcarcinoom na radiotherapie.
 In Hoofdstuk 7 werden de resultaten van 41 patiënten in het eerste jaar na hun 
MRI-geleide focale cryoablatie besproken. De haalbaarheid en bijwerkingen tijdens 
en na de behandeling werden geëvalueerd. Eventuele complicaties werden geclas-
sificeerd volgens het Clavien-gradering systeem voor chirurgische complicaties. 
Daarnaast werden door de patiënten gestandaardiseerde vragenlijsten ingevuld 
zodat (in)continentie (IPSS en ICIQ-SF vragenlijsten), erectiele (dis)functie (IIEF-5 
vragenlijst) en de kwaliteit van leven (FACT-P vragenlijst) voor de behandeling en 6 en 
12 maanden na de MRI-geleide cryoablatie met elkaar vergeleken konden worden. 
De patiënten waren ziektevrij als er geen biochemisch recidief volgens de Phoenix- 
criteria (laagste PSA-waarde +2) te zien was en als er geen klinische, radiologische 
of histopathologisch bewijs was voor een lokaal recidief of metastasen. Alle procedures 
konden worden uitgevoerd. Er was één (2,4%) levensbedreigende complicatie 
(Clavien-graad 4) en één (2,4%) complicatie waarvoor een ingreep onder algehele 
anesthesie (Clavien-graad 3b) nodig was. Twaalf maanden na de MRI-geleide 
cryoablatie waren de ICIQ-SF- (p=0.001) en de IIEF-5 scores (p=0.024) significant 
verslechterd. Dit betekende dat zowel de klachten met betrekking tot incontinentie als 
erectiele disfunctie waren toegenomen. De kwaliteit van leven na 12 maanden was 
daarentegen niet verslechterd. Binnen 6 maanden na de behandeling bleken vijf 
patiënten metastasen te hebben. Waarschijnlijk waren deze al aanwezig tijdens de 
behandeling, maar waren deze toen nog te klein om opgespoord te kunnen worden. 
Twaalf maanden na behandeling waren 23 patiënten (59%) nog ziektevrij. 
 Hoofdstuk 8 beschrijft de studie naar het behandeleffect van MRI-geleide 
laserablatie. Vijf patiënten met nieuw gediagnosticeerd prostaatcarcinoom kregen 
drie weken voor hun radicale prostatectomie een extra behandeling met MRI-geleide 
focale laserablatie. Tijdens de laserablatie werd de totale weefselschade geschat 
met behulp van MRI temperatuurbeelden. Direct na de laserablatie werden er 
T1-gewogen contrastopnamen gemaakt om de totale weefselschade in beeld te 
brengen. De totale weefselschade en de contrastopnamen werden vergeleken met 
de werkelijke weefselschade zoals deze te zien was in de verwijderde prostaat. 
Tussen de weefselschade zoals deze gezien werd op de T1-gewogen contrast-
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opnamen en de werkelijke, histopathologische weefselschade in de verwijderde prostaat 
werd een significante overeenkomst gevonden (r=0,94, p=0,018). De geschatte 
weefselschade op de temperatuurbeelden vertoonde geen significante overeenkomst 
met de histopathologische weefselschade (r=0,33, p=0.583). Op de histopathologische 
beelden van de verwijderde prostaat werd een homogeen, necrotisch gezien dat 
werd omringd door een reactieve overgangszone met een dikte variërend van 1 – 5 
mm. In deze zone werd naast neovascularisatie een verhoogde celdeling gezien, wat 
zou kunnen wijzen op een verhoogde tumoractiviteit. Hieruit werd geconcludeerd dat 
het erg belangrijk is dat de tumor in zijn geheel en met daaromheen een bepaalde 
veiligheidsmarge behandeld wordt.
159
NEDERLANDSE SAMENVATTING
11

Abbreviations
List of publications and presentations
Dankwoord
Curriculum Vitae
Appendices

163
ABBREVIATIONS
Abbreviations
ADC  Apparent diffusion coefficient
ADT  Androgen deprivation therapy
BPH  Benign prostate hyperplasia
CG  Clavien grade
CT  Computed tomography
DCE  Dynamic contrast-enhanced
DRE  Digital rectal examination
DWI  Diffusion-weighted imaging
EBRT  External beam radiation therapy
ESUR  European society of urogenital radiology
FLA  Focal laser ablation
GS  Gleason score
HDR  High dose rate
HIFU  High intensity focused ultrasound
IRE  Irreversible electroporation
MR  Magnetic resonance
MRI  Magnetic resonance imaging
PCa  Prostate cancer
PDT  Photo dynamic therapy
PSA  Prostate specific antigen
QoL  Quality of life
RFA  Radio frequency ablation
RP  Radical prostatectomy
RT  Radiotherapy
SRP  Salvage radical prostatectomy
T  Tesla
T1w  T1-weighted
T1wCE  T1-weigthed contrast-enhanced
T2w  T2-weighted
TRUS  Transrectal ultrasound
US  Ultrasound
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